

1 Mitochondrion of the *Trypanosoma brucei* long slender bloodstream form is  
2 capable of ATP production by substrate-level phosphorylation.

3

4 Taleva Gergana<sup>1,2#</sup>, Husova Michaela<sup>1,2#</sup>, Panicucci Brian<sup>1</sup>, Hierro-Yap Carolina<sup>1,2</sup>, Pineda  
5 Erika<sup>3</sup>, Biran Marc<sup>4</sup>, Moos Martin<sup>5</sup>, Šimek Petr<sup>5</sup>, Butter Falk<sup>6,7</sup>, Bringaud Frederic<sup>3</sup>, Ziková  
6 Alena<sup>1,2\*</sup>

7

8 <sup>1</sup> Institute of Parasitology, Biology Centre CAS, Ceske Budejovice, Czech republic

9 <sup>2</sup> Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech republic

10 <sup>3</sup> Univ. Bordeaux, CNRS, Laboratoire de Microbiologie Fondamentale et Pathogénicité (MFP),  
11 Université de Bordeaux, UMR-5234, Bordeaux, France

12 <sup>4</sup> Univ. Bordeaux, CNRS, Centre de Résonance Magnétique des Systèmes Biologiques  
13 (CRMSB), UMR 5536, Bordeaux, France

14 <sup>5</sup> Institute of Entomology, Biology Centre CAS, Ceske Budejovice, Czech republic

15 <sup>6</sup> Institute of Molecular Biology (IMB), Mainz, Germany

16 <sup>7</sup> Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institute, Greifswald,  
17 Germany

18

19 # these two authors contributed equally

\*Corresponding author: azikova@paru.cas.cz

20

## 21 **Abstract**

22 The long slender bloodstream form *Trypanosoma brucei* maintains its essential mitochondrial  
23 membrane potential ( $\Delta\Psi_m$ ) through the proton-pumping activity of the  $F_0F_1$ -ATP synthase  
24 operating in the reverse mode. The ATP that drives this hydrolytic reaction has long been

25 thought to be generated by glycolysis and imported from the cytosol via an ATP/ADP carrier  
26 (AAC). Indeed, we demonstrate that AAC is the only carrier that can import ATP into the  
27 mitochondrial matrix to power the hydrolytic activity of the F<sub>0</sub>F<sub>1</sub>-ATP synthase. However,  
28 contrary to expectations, the deletion of AAC has no effect on parasite growth, virulence or  
29 levels of  $\Delta\Psi_m$ . This suggests that ATP is produced by substrate-level phosphorylation pathways  
30 in the mitochondrion. Therefore, we knocked out the succinyl-CoA synthetase (SCS) gene, a key  
31 mitochondrial enzyme that produces ATP through substrate-level phosphorylation in this  
32 parasite. Its absence resulted in changes to the metabolic landscape of the parasite, lowered  
33 virulence, and reduced mitochondrial ATP content. Strikingly, these SCS mutant parasites  
34 become more dependent on AAC as demonstrated by a 25-fold increase in their sensitivity to the  
35 AAC inhibitor, carboxyatractyloside. Since the parasites were able to adapt to the loss of SCS in  
36 culture, we also analyzed the more immediate phenotypes that manifest when SCS expression is  
37 rapidly suppressed by RNAi. Importantly, when performed under nutrient-limited conditions  
38 mimicking various host environments, SCS depletion strongly affected parasite growth and  
39 levels of  $\Delta\Psi_m$ . In totality, the data establish that the bloodstream form mitochondrion is capable  
40 of generating ATP via substrate-level phosphorylation pathways.

## 41 **Introduction**

42 The unicellular parasite, *Trypanosoma brucei*, dramatically rewires its metabolism as it  
43 undergoes a complex digenetic life cycle through the tsetse insect vector and various mammalian  
44 hosts [1]. This advantageous adaptation is in response to the varied nutrients encountered as the  
45 extracellular parasite first traverses from the tsetse midgut to the salivary glands before invading  
46 the bloodstream and interstitial spaces of distinct mammalian organs and tissues [2]. In terms of  
47 energy metabolism, the insect forms of the parasite mainly consume amino acids (e.g. proline,  
48 threonine), which are oxidized in its single mitochondrion to succinate, acetate and alanine [3-5].  
49 This generates ATP by both the oxidative and substrate-level phosphorylation pathways [6-9].  
50 On the contrary, the dividing long slender bloodstream form (abbreviated hereafter as BSF)  
51 resides in the glucose-rich environment of the mammalian bloodstream and synthesizes the  
52 majority of their cellular ATP in the cytosol through robust glycolysis [10]. This bioenergetic  
53 switch is essential because the proton-pumping electron transport chain (ETC) complexes III and  
54 IV are absent [11] and complex I does not contribute to the mitochondrial proton motive force in

55 this life cycle stage [12]. Without functional complexes III and IV, the BSF expresses the  
56 trypanosoma alternative oxidase (TAO or AOX) [13]. While this enzyme transfers electrons  
57 from ubiquinol to oxygen, it does not generate a proton motive force. Therefore, ATP cannot be  
58 produced by oxidative phosphorylation via the  $F_0F_1$ -ATP synthase. Consequently, the BSF is a  
59 rare example of an aerobic organism that does not employ its mitochondrion as the powerhouse  
60 of the cell [14].

61 Lacking the enzymes that normally participate in generating the proton motive force, the  
62 conditions dictate that the  $F_0F_1$ -ATP synthase operates in the reverse mode. By hydrolyzing ATP  
63 and utilizing the released energy to pump protons across the inner mitochondrial membrane, this  
64 elegant enzyme maintains the BSF mitochondrial membrane potential ( $\Delta\Psi_m$ ) [15, 16]. The  
65 reverse activity of this multi-subunit protein complex is well known in the aerobic eukaryote  
66 world, but it is usually employed only for a short period of time to overcome sudden changes in  
67 the environment (e.g. hypoxia or anoxia conditions) that result in impaired respiration and  
68 mitochondrial membrane depolarization [17]. Under these conditions, the  $F_0F_1$ -ATP synthase  
69 first reverses its rotation and hydrolyzes the ATP supplied by mitochondrial substrate-level  
70 phosphorylation, a rescue mechanism that protects against cytosolic ATP depletion [18, 19].  
71 However, if the intramitochondrial ATP/ADP ratio decreases and the  $\Delta\Psi_m$  is reduced even more,  
72 the ATP/ADP carrier (AAC) also reverses. These circumstances can deplete cellular ATP as  
73 cytosolic ATP is imported into the mitochondrion to supply the substrate needed for the  $F_0F_1$ -  
74 ATPase activity. This scenario can rapidly lead to cell death if the  $F_0F_1$ -ATPase activity is not  
75 constrained by the inhibitory peptide IF1 [20, 21].

76 Uniquely, *T. brucei* is capable of exploiting the reverse mode of the enzyme for long periods of  
77 time. The hydrolytic activity of  $F_0F_1$ -ATP synthase appears to be the only entity that generates  
78 the  $\Delta\Psi_m$  in BSF, as RNAi silencing of its subunits causes a decrease in  $\Delta\Psi_m$  within 24 hours [16,  
79 22, 23] [24]. Furthermore, inhibition of ATP hydrolysis by the forced expression of the *T. brucei*  
80 homolog of the inhibitory peptide IF1 (TbIF1) decreases the  $\Delta\Psi_m$  below the BSF viability  
81 threshold within 12 hours [25]. Thus, the BSF  $F_0F_1$ -ATP synthase is not an ATP-producing  
82 enzyme but an ATP-consuming enzyme. Therefore, we were intrigued to decipher which  
83 metabolic pathways supply this molecular nanomachine with ATP. There are at least two  
84 possibilities: either ATP is taken from the cytosol and imported into the mitochondrial matrix by

85 an ATP/ADP carrier [26, 27] or the mitochondrion produces the ATP itself through substrate-  
86 level phosphorylation pathways. Because the mitochondrion of the BSF is metabolically poor  
87 when compared with the insect forms [28], it was proposed that the organelle does not participate  
88 in ATP production and that the glycolytically produced ATP is imported from the cytosol.  
89 However, there has been no direct experimental evidence for this assumption.

90 Remarkably, the BSF parasites exhibit ~40-fold lower sensitivity to AAC inhibitors than  
91 dyskinetoplasmic trypanosomes, which lack their mitochondrial genome and thus the proton-  
92 pumping  $F_0F_1$ -ATPase activity [29]. Even though these dyskinetoplasmic trypanosomes fully rely  
93 on the electrogenic exchange of  $ATP^{4-}/ADP^{3-}$  to generate  $\Delta\Psi_m$  [30], the striking difference in  
94 sensitivity to AAC inhibitors raises questions about the role of AAC for BSF mitochondria.  
95 Moreover, new metabolomic and proteomic data suggest that the metabolic potential of the BSF  
96 parasite mitochondrion may be greater than originally thought and may potentially contribute to  
97 intramitochondrial ATP production [31-33]. For example, it was recently established that a  
98 portion of glucose-derived pyruvate and threonine are further metabolized to acetate, an essential  
99 precursor for de novo fatty acid synthesis [34]. Glucose-derived pyruvate and threonine are  
100 metabolized by pyruvate- and threonine dehydrogenases (PDH and TDH), respectively, leading  
101 to the formation of acetyl-Coenzyme A (acetyl-CoA). This energy-rich compound is rapidly  
102 converted to acetate by two redundant pathways. The first employs acetyl-CoA thioesterase  
103 (ACH). The second utilizes acetate:succinate-CoA transferase (ASCT), which is coupled to  
104 succinyl-CoA synthetase (SCS) activity to simultaneously produce mitochondrial ATP [35] [36]  
105 (Fig 1). Isotope-labeled metabolomic data have also shown production of succinate that is not  
106 derived from glucose, suggesting that other carbon sources can be metabolized, such as amino  
107 acids [33]. Interestingly, the BSF consumes significant levels of glutamine from the medium  
108 [32]. Glutamine-derived  $\alpha$ -ketoglutarate can be converted by  $\alpha$ -ketoglutarate dehydrogenase  
109 (KDH) to succinyl-CoA, which is the substrate for ATP-producing SCS. Moreover,  $\alpha$ -  
110 ketoglutarate can be produced by amino acid transaminases. As a precedence, the transitional  
111 short stumpy bloodstream form, cell-cycle arrested parasites primed for the transmission to the  
112 insect host, maintains high levels of intracellular ATP in the presence  $\alpha$ -ketoglutarate possibly by  
113 the substrate phosphorylation [37]. Thus, it is plausible that the mitochondrion of the  
114 proliferative long slender BSF may be also capable of intramitochondrial ATP production (Fig  
115 1).

116 African trypanosomes (*T. brucei* spp, *T. congolense*, *T. vivax*) are parasites of great medical and  
117 veterinary importance. While Human African Trypanosomiasis (HAT) is expected to be  
118 eliminated as a public health problem by 2025 [38], Animal African trypanosomiasis (AAT)  
119 represents an enormous economic burden. While AAT is commonly treated with cationic drugs  
120 (e.g. isometamidium and diminazene) that are sequestered within the mitochondrion [39, 40],  
121 resistance to some of these drugs is linked to parasites with a reduced  $\Delta\Psi_m$  [41-43]. Therefore, it  
122 is critical to understand the molecular mechanisms responsible for the maintenance of the  $\Delta\Psi_m$  in  
123 the infectious forms of trypanosomes. To determine which molecular entities supply ATP to the  
124 reversed F<sub>0</sub>F<sub>1</sub>-ATP synthase, we generated two different null mutant cell lines in which AAC or  
125 SCS was eliminated. Evaluating how the absence of these gene products affects the viability,  
126 bioenergetics and the mitochondrial metabolism of *T. brucei* BSF parasites revealed that the BSF  
127 mitochondrion is capable of ATP production.

## 128 **Results**

### 129 **ATP/ADP carrier is dispensable in BSF *T. brucei* in vitro and in vivo**

130 The *T. brucei* ATP/ADP carrier (AAC, originally named MCP5 [26]) is represented by three  
131 identical and consecutive genes (Tb927.10.14820, -14830, -14840) in the parasite genome. To  
132 determine if the replicative long slender BSF viability depends on the presence of AAC, we  
133 removed all three genes by homologous recombination, resulting in an AAC double knock-out  
134 mutant (AAC DKO) (Fig 2A). We verified the correct genomic integration of the two cassettes  
135 containing antibiotic resistance genes by PCR (Fig 2B) and by Western blot using a specific  
136 polyclonal antibody raised against recombinant *T. brucei* AAC [27] (Fig 2C). The AAC DKO  
137 mutants showed no significant growth effect when grown in the commonly used HMI-11  
138 medium containing a high concentration of glucose (25 mM) (Fig 2D). The same lack of growth  
139 phenotype was observed in the simplified Creek minimal medium (CMM), which, with its 10  
140 mM glucose, represents better, although still well above, the extracellular glucose concentration  
141 in the mammalian host [44] (Fig 2E). Next, we examined the virulence of AAC mutant parasites  
142 by infecting two groups of BALB/c mice with either the parental (BSF 427) or AAC DKO *T.*  
143 *brucei*. The parasitemia levels and the rate of survival were monitored over several days. Neither  
144 group of infected mice survived beyond day 6, indicating that the AAC DKO mutants are fully  
145 virulent in the mouse model (Fig 2F) and thus AAC is dispensable for BSF parasite viability.

146 Since the *T. brucei* BSF mitochondrion has long been assumed to be strictly an ATP consuming  
147 organelle, it was predicted that AAC functions in the reverse mode to supply the mitochondrial  
148 matrix with cytosolic ATP. Once in the mitochondrion, the ATP is hydrolyzed by F<sub>0</sub>F<sub>1</sub>-ATP  
149 synthase to maintain the essential  $\Delta\Psi_m$ . To examine this assumption, we investigated whether  
150 the absence of AAC affects  $\Delta\Psi_m$  in living *T. brucei* parasites. For this purpose, we used the  
151 fluorescent lipophilic dye, tetramethylrhodamine ethyl ester (TMRE), in a non-quenching mode  
152 to analyze the stained parasites by flow cytometry. We detected no difference in the fluorescence  
153 intensity averaged over the entire cell population of BSF 427 and AAC DKO cells grown in  
154 either HMI-11 or CMM media. This demonstrates that AAC DKO parasites maintain their  $\Delta\Psi_m$   
155 at the same level as BSF 427. Treatment with FCCP, a protonophore, induced membrane  
156 depolarization as expected (Fig 2G). To determine if the AAC DKO mutants still maintain their  
157  $\Delta\Psi_m$  by the reverse activity of F<sub>0</sub>F<sub>1</sub>-ATP synthase, the BSF 427 and AAC DKO cells were  
158 incubated for 24 hours with a sublethal concentration of the F<sub>0</sub>F<sub>1</sub>-ATP synthase inhibitor,  
159 oligomycin (250 ng/ml, ~0.5 of the EC<sub>50</sub> for BSF 427 [22, 29]). While this treatment did not  
160 affect the doubling time of BSF 427 or AAC DKO parasites (BSF 427: 6 ± 0.2 hours, AAC  
161 DKO: 6.3 ± 0.3), it did result in a similar reduction of the  $\Delta\Psi_m$  in BSF 427 and AAC DKO  
162 mutants, with values reaching 50±11% and 64±7%, respectively (Fig 2H). Moreover, Alamar  
163 Blue assays revealed that the AAC DKO mutant remains sensitive to oligomycin, with EC<sub>50</sub>  
164 values even lower than BSF 427 (BSF 427 EC<sub>50</sub>: 0.489 µg/ml, AAC DKO EC<sub>50</sub>: 0.155 µg/ml).  
165 These results indicate that the AAC DKO cells still rely on the reverse F<sub>0</sub>F<sub>1</sub>-ATP synthase  
166 activity to maintain their  $\Delta\Psi_m$ .

### 167 **AAC DKO is unable to import ATP into the mitochondrial matrix**

168 To examine whether there is an alternative way for the cytosolic ATP to cross the mitochondrial  
169 inner membrane in the absence of AAC, we assayed the capacity of the BSF 427 and AAC DKO  
170 mitochondrion to generate a  $\Delta\Psi_m$  through the proton-pumping activity of F<sub>0</sub>F<sub>1</sub>-ATP synthase in  
171 the presence of external ATP. We permeabilized the *T. brucei* plasma membrane with 4 µM  
172 digitonin and measured changes in Safranin O fluorescence upon the addition of 1 mM ATP. As  
173 Safranin O is imported into the mitochondrion via a  $\Delta\Psi_m$  dependent manner, the fluorescent dye  
174 undergoes a spectral change that is measured by a fluorimeter. The detected changes in the  
175 fluorescence values are used to estimate the  $\Delta\Psi_m$  [45]. The control BSF 427 cells were able to

176 create and retain a  $\Delta\Psi_m$ , as evidenced by a decrease in safranin O fluorescence. Importantly,  
177 this quenching of safranin O is completely reversed by the addition of carboxyatractyloside  
178 (CATR), the inhibitor of AAC. Subsequent addition of oligomycin before the uncoupler SF 6847  
179 had no further effect on depolarization (Fig 3A, black line). No changes in fluorescence were  
180 detected when the addition of CATR preceded that of ATP, confirming that the decrease in  
181 safranin O fluorescence is dependent on AAC activity (Fig 3A, red line). Meanwhile, the AAC  
182 DKO cell line was unable to generate a  $\Delta\Psi_m$  in the presence of external ATP, indicating that no  
183 ATP was able to enter the mitochondrial matrix. Importantly, a v5-tagged addback of AAC,  
184 expressed from a tubulin gene locus upon the addition of tetracycline, fully rescued the ability to  
185 polarize the inner membrane (Fig 3B). Therefore, *in vitro* assays demonstrate that  
186 extramitochondrial sources of ATP cannot be imported into the organelle in the absence of AAC.

187 To confirm the importance of AAC in live cells, we generated reporter BSF 427 and AAC DKO  
188 cell lines constitutively expressing a firefly luciferase fused with a C-terminal v5 tag. This  
189 heterologous luciferase expression was targeted to either the cytosol (BSF 427\_luc\_cyto and  
190 AAC DKO\_luc\_cyto) or the mitochondrion (BSF 427\_luc\_mito and AAC DKO\_luc\_mito). To  
191 promote efficient mitochondrial localization of the luciferase, its gene was fused with the known  
192 mitochondrial localization signal of the iron-sulphur cluster assembly protein, ISCU [46]. The  
193 expression of the tagged luciferases and their appropriate localization in the cytosol or  
194 mitochondrion were verified by western blotting (Fig 3C). Next, we monitored the amounts of  
195 ATP in the cytosol of the BSF 427\_luc\_cyto and AAC DKO\_luc\_cyto cell lines. The expressed  
196 luciferase catalyzes the oxidation of membrane-permeable D-luciferin. This produces  
197 bioluminescence proportional to the amount of ATP present in the live cells. Supplementing the  
198 buffer of the intact cells with glucose produced an increase in the cytosolic ATP levels in both  
199 cell lines, demonstrating the immediate contribution to the cellular ATP pool by glycolysis (Fig  
200 3D). Interestingly, the AAC DKO\_luc\_cyto cell line had higher levels of ATP compared to BSF  
201 427\_luc\_cyto parasites (Fig 3E). This discrepancy could be the result of more ATP being  
202 sequestered within the cytosol in the absence of mitochondrial ATP import by AAC. Indeed, in  
203 the case of cell lines expressing mitochondrially localized luciferase, the addition of glucose  
204 caused a spike in mitochondrial ATP levels in the BSF 427\_luc\_mito cell line, but not in AAC  
205 DKO\_luc\_mito parasites (Figs 3F, 3G). This result verifies that no glucose-derived ATP can be  
206 imported into the mitochondrial matrix without AAC.

207 **The absence of AAC does not significantly alter the proteomic or metabolomic landscapes**  
208 **in BSF *T. brucei***

209 To explore if AAC DKO parasites underwent specific compensatory adaptations that would be  
210 reflected by changes in the parasite proteomic landscape, we performed label-free quantitative  
211 proteomic analyses. Quadruplicates of BSF 427 and ACC DKO cell lysates were processed using  
212 a four-hour liquid chromatography gradient coupled with high-resolution mass spectrometry.  
213 The resulting datasets were analyzed by MaxLFQ. We quantified 3,654 protein groups with a  
214 minimum of 2 peptides (1 unique) that were present in at least two out of four replicates. Overall,  
215 the expression of only 76 proteins was significantly downregulated in AAC DKO, most of which  
216 were hypothetical or ribosomal proteins. A total of 44 proteins were significantly upregulated (<  
217 1.5 times,  $p < 0.05$ , S1 Fig, S1 Table). From these candidates, only the following proteins were  
218 relevant to the scope of this study: succinate dehydrogenase subunit 1 (SDH1, Tb927.8.6580),  
219 isocitrate dehydrogenase (IDH, Tb927.8.3690), and amino acid transporter (Tb927.8.8230).  
220 Furthermore, some subunits of PDH, KDH, branched-chain ketoamino acid dehydrogenase and  
221 mitochondrial pyruvate carrier 2 (MPC2) were also upregulated, although with a  $p$ -value lower  
222 than 0.05 (S1 Fig, S1 Table). Additional mitochondrial enzymes involved in the oxidative  
223 metabolism of glucose-derived pyruvate, threonine, and glutamine/glutamate were found  
224 unchanged or only slightly affected by the absence of AAC (e.g. malic enzyme (ME)) (S1 Fig).  
225 Therefore, we could not identify any obvious known bioenergetic pathways that would indicate  
226 that cells lacking AAC need to adapt and activate some compensatory pathways.

227 In agreement with the proteomics dataset, our metabolomic analysis of the AAC DKO mutant  
228 revealed no significant changes in the selected 123 metabolites involved in carbohydrate and  
229 amino acid catabolism or in energy metabolism (S2 Table). The only exceptions were some  
230 intermediate metabolites of amino acid metabolism that were upregulated, while ribose was  
231 strongly downregulated (S1 Fig). In addition, we also detected a slight accumulation of ATP (1.4  
232 times,  $p$ -value = 0.02) and GTP (1.7 times,  $p$ -value = 0.008) at the cellular level, suggesting that  
233 BSF AAC operates minimally in the reverse mode and in its absence, mitochondrial amino acid  
234 metabolism rises marginally. Despite these few observed changes, our results indicate that the  
235 AAC DKO mutant does not undergo major restructuring of its global proteomic and  
236 metabolomic landscapes in response to the absence of AAC.



237 **AAC DKO is more sensitive to methyltriphenylphosphonium (TPMP), an inhibitor of  $\alpha$ -**  
238 **ketoglutarate dehydrogenase**

239 The ability of the AAC DKO mutant to maintain the  $\Delta\Psi_m$  despite its inability to import cytosolic  
240 ATP to the mitochondrial matrix suggests an intramitochondrial source of ATP. This ATP can be  
241 generated by substrate-level phosphorylation, with the ATP-producing enzyme SCS being the  
242 best candidate (Fig 1). To determine if the ASCT/SCS substrate-level phosphorylation pathway  
243 is more important for the AAC DKO mutant, we probed the sensitivity of the AAC DKO and  
244 BSF 427 cells to known inhibitors of PDH and TDH. We found no differences in the sensitivity  
245 of BSF 427 or AAC DKO cells to the PDH inhibitor, sodium arsenite (BSF 427  $EC_{50} = 0.22 \mu\text{M}$   
246 vs AAC DKO  $EC_{50} = 0.19 \mu\text{M}$ ). Moreover, the AAC DKO parasites were not more sensitive to  
247 any of the TDH inhibitors we applied: quinazolinecarboxamide compound QC1 (BSF 427  $EC_{50}$   
248 =  $11.3 \mu\text{M}$  vs AAC DKO  $EC_{50} = 9.7 \mu\text{M}$ ) or tetraethyl thiuram disulphide (TETD) (BSF 427  
249  $EC_{50} = 9.9 \mu\text{M}$  vs AAC DKO  $EC_{50} = 9.4 \mu\text{M}$ ) [47]. Since the PDH and TDH activities are  
250 complementary and can compensate for each other [34], it is not surprising that we did not detect  
251 any change in the sensitivity of these inhibitors. In contrast, the AAC DKO mutants were 18-fold  
252 more sensitive to methyltriphenylphosphonium chloride (TPMP) treatment (Fig 4A), a  
253 compound that inhibits KDH [48] (Fig 1). Importantly, AAC DKO parasites expressing an  
254 ectopic v5-tagged AAC had TPMP  $EC_{50}$  values return to the sensitivity observed in the BSF 427  
255 cell line (Fig 4A). This confirms that the increased significance of KDH is due to the loss of  
256 AAC. Because KDH generates succinyl-CoA, the substrate for ATP-producing SCS, the  
257 increased importance of KDH activity in the absence of AAC would suggest that the AAC in  
258 BSF cells operates to some extent in the reverse mode. Without the normal contribution of AAC  
259 to the mitochondrial ATP pool, the parasite is more dependent on mitochondrial ATP substrate-  
260 level phosphorylation. The importance of KDH-linked mitochondrial substrate-level  
261 phosphorylation is further highlighted by an additional six-fold enhanced sensitivity to TPMP  
262 when ASCT expression was suppressed in the background of the AAC DKO parasites (Figs 4B  
263 and 4C). Our results suggest that cells lacking AAC are more dependent on the two  
264 mitochondrial substrate-level phosphorylation pathways linked by the activity of SCS (Fig 1).

265 **SCS is expressed and active in the BSF cells**

266 SCS is a heterodimer consisting of an  $\alpha$ -subunit that binds CoA and a  $\beta$ -subunit that is involved  
267 in the generation of ATP. To assess the importance of SCS to the BSF parasites, we generated a  
268 double knockout of the ATP-forming  $\beta$ -subunit of SCS (Tb927.10.7410) (Fig 5A). Replacement  
269 of both SCS  $\beta$ -subunit alleles with resistance markers was verified by PCR (Fig 5B). The  
270 absence of the gene product was further confirmed by Western blot using a specific antibody  
271 raised against the recombinant SCS  $\beta$ -subunit (Fig 5C). The SCS enzyme was localized to the  
272 mitochondrial matrix as expected (Fig 5D). We also developed an *in vitro* colorimetric assay that  
273 measures the amount of CoA produced when the SCS from soluble mitochondrial fractions are  
274 incubated with the substrates succinyl-CoA and ADP. The SCS activity measured in both the  
275 BSF 427 and AAC DKO cell lines was comparable. Importantly, no SCS activity was detected in  
276 the SCS DKO cells, confirming the specificity of this assay and the absence of an alternative  
277 gene encoding the  $\beta$  subunit of SCS (Fig 5E).

#### 278 **SCS DKO parasites display a reduced virulence in a mouse model**

279 The SCS DKO mutants were viable when cultured in both HMI-11 and CMM media (Figs 5F  
280 and 6G). To investigate whether SCS is essential for the establishment of infection in animals,  
281 we inoculated groups of seven mice with BSF 427 and SCS DKO cells. Mice infected with the  
282 control parasites all had to be euthanized for ethical reasons 5-6 days after intraperitoneal  
283 injection because a parasitemia of  $10^8$  cells/ml was reached. In the case of the SCS null mutants,  
284 four of the infected mice were not sick after two weeks and three survived the infection (Fig 5H).  
285 The SCS DKO addback cell line (western blot confirmed, Fig 5I) expressing SCS from the  
286 tubulin locus was again fully virulent and behaved the same as the BSF 427 parasites. This  
287 confirms that the virulence defect was specifically due to the loss of SCS (Fig 5J).

#### 288 **Metabolomic analysis of SCS mutants reveals changes in the levels of relevant metabolites**

289 To identify possible metabolic changes in SCS DKO trypanosomes at the protein level, we  
290 performed quantitative label-free proteomic analyses of SCS DKO whole cell lysates and  
291 compared them with BSF 427 samples. Among the 3,654 proteins identified by at least two  
292 peptides, only 17 and 21 proteins were up- or down-regulated by more than 1.5-fold,  
293 respectively, in the mutant cell line ( $p < 0.05$ ). This corresponds to approximately just 0.5% of  
294 the proteome. Due to the small size of significantly altered hits, the GO ontology enrichment

295 analyses did not reveal any enrichment of GO term categories (S2 Fig, S1 Table). Notably, one  
296 of the downregulated proteins was also SCS subunit  $\alpha$ , presumably due to the lack of its  
297 heterodimer partner, subunit  $\beta$ . In conclusion, similar to AAC DKO, there is no major  
298 remodeling of metabolic pathways in the SCS DKO mutant that would be reflected by a change  
299 in the steady-state abundance of their enzymatic components.

300 We also performed a targeted metabolomic analysis of the SCS DKO mutant and BSF 427  
301 parasites. Of the 127 metabolites analyzed, we found an enrichment of acetyl-CoA (2.4-fold) and  
302  $\alpha$ -ketoglutarate (1.5-fold). This finding demonstrates the veracity of the metabolomics approach,  
303 as these metabolites lie just upstream of the two different substrate-level phosphorylation  
304 pathways that depend on SCS. Furthermore, the TCA cycle metabolites (succinate, fumarate and  
305 malate) that are synthesized immediately downstream of SCS were all strongly downregulated.  
306 Interestingly, we also observed increases of oxaloacetate (5.4-fold) and glutamate (1.6-fold), a  
307 possible source of  $\alpha$ -ketoglutarate, along with decreased levels of aspartate (0.6-fold). This  
308 finding suggests a downregulation of the mitochondrial aspartate aminotransferase, an important  
309 enzyme in amino acid metabolism that is normally expressed in BSF cells. The aspartate  
310 aminotransferase is a key enzyme in the malate-aspartate shuttle, which is a biochemical system  
311 designed to balance the levels of mitochondrial and cytosolic NADH. Alterations were also  
312 observed in metabolites belonging to the pentose phosphate pathway and amino acid metabolism  
313 (S2 Fig, S3 Table). Importantly, our analysis doesn't distinguish between glycosomal, cytosolic,  
314 and mitochondrial dicarboxylic acid pools. It's unlikely that the SCS absence affects the  
315 glycosomal succinate reduction pathway, which functions mainly as a redox balancer for  
316 glycolysis. Nevertheless, more metabolomic studies with labeled-carbon sources (e.g., glucose,  
317 glutamine) are needed to pinpoint the metabolites' exact origin and location.

### 318 **The excretion of acetate is abolished in the SCS DKO mutant**

319 Next, we wanted to closely examine if either of the SCS substrate-level phosphorylation  
320 pathways contribute to the levels of known BSF excreted metabolic end-products. Therefore, we  
321 incubated BSF 427, SCS DKO and AAC DKO cells in [U- $^{13}\text{C}$ ]-enriched glucose-containing PBS  
322 and used  $^1\text{H}$  NMR spectrometry to quantify the amount of  $^{13}\text{C}$ -enriched end-products produced  
323 via glucose metabolism that were excreted into the medium. BSF 427 cells excreted  
324 predominantly high amounts of pyruvate (79.8%) and to a lesser amount alanine (10.6%), lactate

325 (4.1%), acetate (3.9%) and succinate (1.6%) (Fig 6A, left panel). Analysis of the SCS DKO  
326 mutant revealed that there were no significant changes in the excretion of pyruvate (82.8%),  
327 alanine (10.7%), succinate (1.2%), and lactate (5.0%). However, the excreted acetate derived  
328 from glucose was completely abolished (Fig 6B, left panel). Since acetate can also be produced  
329 from threonine, we utilized an alternative <sup>1</sup>H NMR spectrometry method in which each cell line  
330 was incubated with equal amounts (4 mM) of both uniformly [<sup>13</sup>C]-enriched glucose and  
331 unenriched threonine to distinguish the metabolic origin of the excreted acetate (Figs 6A and 6B,  
332 middle and right panel). Interestingly, acetate excretion from both [U-<sup>13</sup>C]-enriched glucose and  
333 unenriched threonine was almost abolished in the SCS DKO cell line, with only residual  
334 amounts of threonine-derived acetate detected. This confirms that the ASCT/SCS cycle coupled  
335 to ATP generation is the primary source of acetate that is excreted. Because SCS DKO cells did  
336 not exhibit a growth phenotype in either HMI-11 or CMM medium, we suggest that the activity  
337 of ACH in SCS DKO cells maintains the intracellular acetate levels necessary for *de novo*  
338 biosynthesis of fatty acids in the absence of SCS (Fig 1) [4]. Unlike the SCS DKO mutant that  
339 resulted in significant metabolic changes, we did not observe any changes in glucose- and  
340 threonine-derived metabolic end products in the AAC DKO cell line (Fig 6C, S4 Table). This is  
341 consistent with the metabolomic data (S1 Fig, S2 Table), suggesting that the absence of AAC is  
342 well tolerated by the BSF cells as mitochondrial substrate-level phosphorylation pathways are  
343 able to fully compensate for its loss.

#### 344 **SCS DKO parasites have reduced mitochondrial ATP levels, but maintain normal levels of** 345 **$\Delta\Psi_m$**

346 To further explore the contributions of mitochondrial substrate-level phosphorylation in BSF  
347 parasites, we measured the mitochondrial ATP levels in SCS DKO parasites and compared them  
348 with BSF 427 and AAC DKO cells. For this purpose, we generated SCS DKO cells  
349 constitutively expressing a mitochondrial v5-tagged luciferase. The expression and localization  
350 of the mitochondrial luciferase was verified in the same manner as the mitochondrial luciferase-  
351 expressing BSF 427 and AAC DKO cells (Figs 2C and 7A). In all three cell lines, the  
352 mitochondrial luciferase expression levels were comparable, without any statistically significant  
353 differences. This consistency in enzyme expression allowed us to compare mitochondrial ATP  
354 levels between the different cell lines (Figs 7B and 7C). Unlike the previous experiments in Fig

355 2D-G, where we measured the dynamics of glucose-induced ATP production, we now measured  
356 the intramitochondrial steady-state ATP levels of the cell lines. The reaction was initiated by the  
357 addition of D-luciferin. As the luciferin enters the cell, the amount of emitted light will rapidly  
358 increases until it reaches a plateau after a certain amount of time depending on the cell line (Fig  
359 7D). The luminescence emissions at the plateau for each cell line from numerous independent  
360 experiments were plotted as a column graph (Fig 7E). The mitochondrial ATP levels in BSF 427  
361 and AAC DKO reached similar levels. Knowing that the mitochondrion of AAC DKO is not  
362 capable of importing ATP, this ATP pool must be produced intramitochondrially. Importantly,  
363 statistically less ATP was detected in the mitochondrial matrix of the SCS DKO mutant cells,  
364 when compared to AAC DKO and BSF 427 cells (Fig 7E). Without the possibility to produce  
365 ATP by substrate-level phosphorylation, it is likely that this ATP pool is generated by the reverse  
366 activity of AAC.

367 The reverse AAC activity is apparently capable of providing a sufficient amount of ATP to  
368 maintain the  $\Delta\Psi_m$ , as no significant difference was detected in the fluorescence intensity of  
369 TMRE-stained BSF 427 and SCS DKO cell populations grown in either HMI-11 or CMM  
370 medium (Fig 7F). Furthermore, the ATP-induced polarization of the mitochondrial inner  
371 membrane in SCS DKO digitonin-permeabilized cells followed the same pattern as in BSF 427  
372 cells, suggesting that AAC is able to import ATP into the mitochondrion and this ATP is used to  
373 energize the membrane using  $F_0F_1$ -ATP synthase (Figs 7G and 7H).

#### 374 **SCS DKO cells are dependent on ATP import from the cytosol**

375 If mitochondrial substrate-level phosphorylation pathways contribute to the BSF mitochondrial  
376 ATP pool under normal physiological conditions, then the SCS DKO cell line must implement a  
377 compensatory mechanism to maintain the  $\Delta\Psi_m$ . Therefore, we examined if SCS DKO parasites  
378 become more dependent on the reverse AAC activity to import the necessary ATP into the  
379 mitochondrial matrix. Indeed, an SCS DKO cell viability assay demonstrated that these mutants  
380 are more sensitive to CATR and bongkreikic acid, both of which are specific inhibitors of AAC.  
381 Compared to BSF 427, the  $EC_{50}$  values of SCS DKO parasites were ~25-fold lower in the case of  
382 CATR and ~5-fold lower for bongkreikic acid (Figs 8A and B). Consistent with this observation,  
383 the ASCT DKO cell line, which is defective in only one of the two mitochondrial substrate-level  
384 phosphorylation pathways, demonstrated only a 10-fold higher sensitivity to CATR compared to

385 BSF 427 (Fig 8A). Tetracycline-induced expression of SCS in the background of the SCS null  
386 mutant restored the original EC<sub>50</sub> values for CATR, confirming that the observed phenotype in  
387 CATR-sensitivity was due to the absence of SCS (Figs 8C and 8D).

388 In summary, it appears that *T. brucei* BSF parasites have two alternative options for  
389 mitochondrial ATP provision, intramitochondrial ATP production by substrate-level  
390 phosphorylation and ATP import from the cytosol via AAC. To test the essentiality of this  
391 intriguing functional interplay, we attempted to silence AAC expression by RNAi in the SCS  
392 DKO background, while also conversely pursuing to silence SCS expression in the AAC DKO  
393 background. Unfortunately, our numerous attempts failed to generate selected transfectants that  
394 retained a robust tetracycline-induced silencing of the targeted gene. While an extremely  
395 unsatisfactory result, we interpret this phenomenon to indicate that any expression of dsRNA in  
396 the absence of tetracycline during the selection process causes a lethal phenotype. Therefore, it is  
397 likely that these two pathways act complementarily to each other and the absence of both is not  
398 consistent with the survival of *T. brucei* parasites under the conditions used.

#### 399 **Mitochondrial production of ATP by substrate-level phosphorylation is essential under** 400 **glycerol-rich growth conditions.**

401 In addition to glucose, the dividing BSF can also use glycerol as an energy and carbon source  
402 [49, 50]. Nevertheless, the growth rate of BSF 427 is significantly reduced when grown in  
403 glycerol-rich (10 mM) medium (CMM\_gly) (Fig 9A). This is due to the limited capacity of BSF  
404 *T. brucei* to metabolize glycerol compared to glucose, which results in a slightly lower yield of  
405 cytosolic ATP compared to cells grown in CMM medium containing 10 mM glucose  
406 (CMM\_glc). Interestingly, BSF grown in CMM\_gly excrete more acetate and succinate than  
407 those grown in CMM\_glc, suggesting a higher activity of these mitochondrial metabolic  
408 pathways [49]. Therefore, we further investigated the importance of SCS for cells grown in  
409 CMM\_gly. The BSF 427 and AAC DKO cells were able to adapt to glycerol conditions well,  
410 albeit they grow with a slower doubling rate. In contrast, the SCS DKO parasites were never able  
411 to establish an adapted culture that actively divided (Fig 9A). Therefore, we wanted to determine  
412 if lower cytosolic ATP yields further reduced the rate of AAC to import ATP into the  
413 mitochondrion. This would require BSF *T. brucei* grown in glycerol media to rely more on  
414 mitochondrial substrate-level phosphorylation to provide its own pool of ATP for the F<sub>1</sub>F<sub>0</sub>-ATP

415 synthase to hydrolyze and maintain the  $\Delta\Psi_m$ . To investigate the primary effect of SCS depletion,  
416 we generated RNAi cells to silence SCS expression of cultures grown in either HMI-11,  
417 CMM\_glc or CMM\_gly. The efficiency of the RNAi-mediated downregulation of SCS was  
418 verified under all three growth conditions by Western blot using specific antibodies (Fig 9B).  
419 The propagation of the SCS RNAi cell line grown in HMI-11 medium was not affected by the  
420 addition of tetracycline (Fig 9C). Furthermore, we did not detect any decrease in the  $\Delta\Psi_m$  by  
421 flow cytometry in TMRE-stained noninduced and tetracycline-induced cells (Fig 9D). However,  
422 silencing of SCS in CMM\_glc medium resulted in an even longer doubling time of the RNAi-  
423 induced cell population. Compared with BSF 427 cells, the  $\Delta\Psi_m$  was decreased by  
424 approximately 30% in cells induced for 5 days, which most likely contributed to the mild growth  
425 phenotype of these cells. Most importantly, SCS RNAi cells grown in CMM\_gly exhibited a  
426 severe growth phenotype associated with a sharp decrease in  $\Delta\Psi_m$  at days 1, 2, and 3 after  
427 induction (Figs 9C and 9D). In this case,  $\Delta\Psi_m$  values fell below the minimum threshold required  
428 for *T. brucei* viability *in vitro* [22, 29].

429 Our data clearly indicate that the functional interplay between AAC and an ATP-producing SCS  
430 depends on the environment. When the parasites encounter environments with lower glucose  
431 concentrations or other carbon sources (e.g. glycerol) that yield lower cytosolic ATP levels, the  
432 BSF *T. brucei* relies on mitochondrial substrate-level phosphorylation pathways as it cannot  
433 augment its mitochondrial ATP pools by using the reverse AAC activity to withdraw ATP from  
434 the cytosol. This is probably also true when the parasites multiply in the bloodstream of their  
435 mammalian host, where they are exposed to various challenges and are therefore likely to  
436 consume greater quantities of cytosolic ATP. In agreement with this, the SCS DKO mutants are  
437 less virulent in the mouse model. The ability of AAC to reverse its activity depends on the levels  
438 of  $\Delta\Psi_m$ , cytosolic ATP levels and the ATP/ADP ratio in the mitochondrial matrix. Therefore, the  
439 parasite bioenergetics regulates the major contributing pathways of ATP provision that are fully  
440 compensatory when the parasite is in glucose-rich HMI-11 culture conditions. However, when in  
441 *in vivo* or CMM\_gly culture conditions, our data show that the mitochondrial substrate-level  
442 phosphorylation pathways become more important for parasite survival. From all the data  
443 together, we can conclude that the BSF mitochondrion is capable of producing ATP.

## 444 **Discussion**

445 Historically, it was purported that maintenance of the *T. brucei* long-slender BSF  $\Delta\Psi_m$  occurred  
446 via the proton-pumping  $F_0F_1$ -ATP synthase hydrolyzing mitochondrial ATP imported from the  
447 cytosol by the reverse activity of AAC. This notion that the organelle only consumes ATP has  
448 persisted through the *T. brucei* literature for decades. However, the widespread assumption that  
449 the long slender BSF possesses a simplified mitochondrion has recently been challenged by  
450 proteomic and metabolomic data suggesting that certain metabolic pathways can be activated  
451 under permissible environmental conditions [11]. High flexibility and adaptability of the parasite  
452 organelle can be beneficial for the parasite when adapting to new host environments (e.g. when  
453 populating adipose tissue or skin) [51, 52]. Indeed, the discovery of a mitochondrial acetate  
454 production pathway that is linked to an ATP-producing activity, has questioned this classical  
455 view {Mazet, 2013 #9867;Mochizuki, 2020 #16213;Nascimento, 2023 #17065} [34, 36, XX].

456 The confounding factor of the *T. brucei* BSF  $\Delta\Psi_m$  centers on the directionality of AAC. It has  
457 been clearly demonstrated that due to the cellular conditions (mitochondrial matrix ATP/ADP  
458 ratio and  $\Delta\Psi_m$ ), the BSF  $F_0F_1$ -ATP synthase has reached its reversal potential ( $E_{rev\_ATPase}$ ) and  
459 hydrolyzes ATP to generate a  $\Delta\Psi_m$  between -150 to -180 mV [15, 16]. Intriguingly,  
460 mathematical modeling of mammalian mitochondria undergoing mitochondrial membrane  
461 depolarization induced by ETC inhibition or hypoxia showed that the  $F_0F_1$ -ATP synthase first  
462 reaches its  $E_{rev\_ATPase}$  value before the conditions also dictate AAC reversal. Under this  
463 circumstance, mitochondrial ATP is generated by mitochondrial substrate-level phosphorylation.  
464 If the  $\Delta\Psi_m$  shifts to even less negative values or the balance between the ATP/ADP ratio in the  
465 mitochondrial matrix and the ATP levels in the cytosol is further disturbed, then AAC will also  
466 reverse ( $E_{rev\_AAC}$ ) [19]. These mathematical models therefore suggest that while the BSF  $F_0F_1$ -  
467 ATP synthase operates in the reverse mode, this activity may not be dependent on the reverse  
468 mode of AAC. Indeed, we demonstrate that AAC DKO *T. brucei* BSF cells are viable *in vitro*  
469 and fully virulent in a mouse model, suggesting that the import of cytosolic ATP into the  
470 mitochondrion is dispensable.

471 Our data also clearly show that AAC is the only carrier that can import ATP into the  
472 mitochondrial matrix since the addition of high ATP concentrations (1 mM) did not induce  
473 mitochondrial membrane polarization in the AAC DKO parasites with permeabilized plasma  
474 membranes. To demonstrate this phenomenon in another way, we treated intact BSF 427 cells



475 resuspended in a defined buffer with external glucose to stimulate cytosolic generations of ATP.  
476 Since these cells were engineered with luciferase targeted to the mitochondrion, we detected that  
477 this ATP was imported into the mitochondrial matrix. However, there was no detected increase  
478 in the mitochondrial ATP levels in the AAC DKO mutants also expressing mitochondrial  
479 luciferase. Therefore, in the case of the AAC DKO parasites, the standard culture medium and  
480 host environment must provide enough nutrients to support mitochondrial ATP production by  
481 mitochondrial substrate-level phosphorylation pathways that are powerful enough to provide  
482 sufficient amounts of ATP to maintain the  $\Delta\Psi_m$  at levels compatible with full parasite virulence  
483 (Fig 10B).

484 Although the metabolomic changes in the AAC DKO parasites may indicated to some extent the  
485 higher activity of mitochondrial metabolic pathways linked to ATP production, the determined  
486 levels of metabolic end-products (i.e. pyruvate, acetate, succinate and alanine) showed no  
487 significant changes. This lack of a striking metabolic remodeling in order to adapt to its absence,  
488 suggests that in the absence of AAC, the BSF mitochondrion is capable of being fully  
489 independent of the cytosolic supply of ATP. Therefore, it seems that AAC does not operate at a  
490 high rate in the reverse mode under physiological conditions (no striking phenotype in AAC  
491 DKO cells) (Figs 10A and 10B). However, it appears that AAC can increase the rate of  
492 mitochondrial ATP import, whenever the mitochondrial substrate-level phosphorylation  
493 pathways are not able to provide enough ATP. High levels of the cytosolic ATP allow for an  
494 immediate reversal of AAC, in which the cytosolic ATP pool contributes to the  $\Delta\Psi_m$ . This is  
495 exemplified in the SCS DKO cell line, where the mitochondrial ATP/ADP ratio is decreased.  
496 Indeed, our luciferase-based assay showed lower mitochondrial steady-state ATP levels in the  
497 SCS DKO parasites when compared to BSF 427 and AAC DKO cells. Since we measured the  
498 same  $\Delta\Psi_m$  values in each of these cell lines (Figure 10C), the AAC activity is fully reversed to  
499 import ATP in compensation for the loss of SCS (Fig 10C). The increased dependence on the  
500 reverse rate of AAC is evident by the dramatic increase in sensitivity to the AAC inhibitor,  
501 CATR.

502 Based on the metabolic pathways mapped to the parasite mitochondrion [32-34], there are at  
503 least two options for generating the succinyl-CoA substrate required for the ATP-producing  
504 SCS. First, succinyl-CoA can be produced by ASCT enzyme from the pyruvate- and threonine-

505 derived acetyl-CoA. The importance of the ASCT/SCS cycle for the ATP/ADP ratio in  
506 mitochondrial matrix is supported by the observation that ASCT DKO parasites are 10-times  
507 more sensitive to CATR compared to BSF 427. Originally, the metabolic pathways leading to the  
508 production of acetyl-CoA were studied from the point of acetate production, the essential  
509 precursor for de novo fatty acid biosynthesis [53]. Indeed, when both pathways leading to acetyl-  
510 CoA were genetically impaired, growth of BSF cells in HMI-11 medium is strongly affected  
511 because of the inability to produce acetate [34]. Interestingly, excretion of acetate was greatly  
512 reduced but not fully abolished in SCS DKO, suggesting that this baseline level of acetate  
513 production is due to the ACH activity and sufficient to support fatty acid biosynthesis without  
514 affecting parasite growth rate [5] [54] [7].

515 The second potential source of succinyl-CoA could be derived from  $\alpha$ -ketoglutarate by KDH, an  
516 enzyme with an enigmatic function in BSF cells [55]. The  $\alpha$ -ketoglutarate can be derived from  
517 glutamine, an amino acid that is consumed in significant amounts [32]. Another possible source  
518 of  $\alpha$ -ketoglutarate are the transamination reactions employing alanine and aspartate  
519 aminotransferases. Alanine aminotransferase is probably essential for BSF cells, as BSF  
520 parasites excrete significant amounts of alanine from pyruvate. Although it is a cytosolic enzyme  
521 [56], [57], the TrypTag data places this enzyme also into the mitochondrial matrix {Billington,  
522 2023 #16985;Pyrih, 2023 #17060} [58, XX]. In addition,  $\alpha$ -ketoglutarate should also be  
523 considered a potentially excellent external source of carbon, as recently observed for PCF  
524 trypanosomes [5].

525 In conditions when glycerol is the main carbon source, the BSF parasites can utilize it in a  
526 similar manner as glucose by converting it into pyruvate, alanine, acetate and succinate, as  
527 observed for glucose. To produce similar amounts of cytosolic ATP, twice as much glycerol (a  
528 three-carbon compound) must be metabolized as glucose (a six-carbon compound). However, the  
529 BSF 427 strain consumes only 1.5-times more glycerol than glucose when grown in CMM\_gly  
530 and CMM\_glc, respectively. This explains the significant growth delay observed in parasites  
531 cultivated in CMM\_gly [49]. Interestingly, the absolute amounts of acetate produced in  
532 CMM\_gly and CMM\_glc is similar (283 *versus* 262 nmol/h/10<sup>8</sup> cells [49]). This suggests that  
533 maintaining mitochondrial substrate-level phosphorylation is important, especially when  
534 cytosolic ATP is reduced as expected in CMM\_gly. This hypothesis is in agreement with the

535 observation that the SCS DKO cells were not able to establish a proliferative culture in  
536 CMM\_gly medium and the SCS RNAi induced cells exhibited a strong growth retardation  
537 followed by a significant decrease of  $\Delta\Psi_m$ . Indeed, the glycerol-induced reduction of the  
538 cytosolic ATP levels may create conditions under which the reverse AAC activity is no longer  
539 sufficient to compensate for the absence of mitochondrial substrate-level phosphorylation (Fig  
540 10D). Alternatively, we cannot exclude that the reverse AAC activity significantly depletes the  
541 cytosolic ATP pool to levels that are detrimental to the parasite.

542 In summary, we can conclude that BSF *T. brucei* exhibit an amazing flexibility in their cellular  
543 bioenergetics, which enables the parasite to quickly adapt and survive various challenging  
544 environments of its mammalian host by responding to sudden changes in intracellular ATP levels  
545 while still maintaining viable levels of the  $\Delta\Psi_m$  across the mitochondrial inner membrane.

## 546 **Material and methods**

### 547 **Trypanosoma cultures**

548 *T. brucei brucei* bloodstream Lister 427 form (BSF 427) and genetic derivatives thereof were  
549 used in this study. The long slender monomorphic BSF were cultured in HMI-11, Creek Minimal  
550 Medium (CMM) containing 10 mM glucose (CMM\_glc) or 10 mM glycerol (CMM\_gly)  
551 supplemented with 10% heat-inactivated fetal bovine serum (FBS) at 37°C in the presence of 5%  
552 CO<sub>2</sub>. The genetically modified parasites were cultivated in HMI-11 medium in the presence of  
553 appropriate antibiotics to maintain their genetic background (G418 in 2.5 µg/ml, hygromycin in  
554 5 µg/ml, puromycin in 0.1 µg/ml, phleomycin in 2.5 µg/ml, and tetracycline in 1 µg/ml). When  
555 needed, the cells were transferred to CMM\_glc or CMM\_gly media and maintained for two  
556 weeks before any experiments were performed (except for the experiment shown in Fig 9A). The  
557 cells were always kept in a logarithmic growth phase and harvested at a density of 0.7-1.4 x 10<sup>6</sup>  
558 cells/ml.

### 559 **Plasmids and generation of genetically modified cell lines.**

560 The AAC double knock-out (DKO) and SCS DKO were generated by two rounds of homologous  
561 recombination using gene knock-out (KO) cassettes conferring either neomycin (G418) or  
562 hygromycin resistance. The gene cassettes were derived from the pLEW13 and pLEW90 vectors,  
563 respectively [59]. To direct the allele replacement, the KO cassettes were flanked by short

564 sequences of either AAC (Tb92710.14820/-30/-40) or SCS subunit  $\beta$  (Tb927.10.7410) 5' and 3'  
565 untranslated regions (UTR) that were identified with TritypDB. The UTR fragments were  
566 amplified by PCR from BSF 427 genomic (g)DNA with 5'UTR\_forward and reverse or  
567 3'UTR\_forward and reverse primers (S5 Table). The amplicons were then digested with Not I  
568 and MluI restriction enzymes (5'UTRs) or XbaI and StuI (3'UTRs) before sequentially ligated  
569 into the pLEW13 plasmid that contains genes for neomycin-resistance and T7 RNA polymerase  
570 gene. The final pLEW13\_AAC\_5'/3'UTRs and pLEW13\_SCS\_5'/3'UTRs constructs were  
571 linearized with Not I and electroporated with human T cell nucleofector solution (AMAXA) into  
572 BSF 427 to generate a single KO cell line. The transfected cells were serially diluted after 16  
573 hours of recovery and selected with 2.5  $\mu$ g/ml G418. To generate the double knock-out, the  
574 hygromycin-resistance cassette containing the tetracycline repressor under T7 RNAP promoter  
575 was excised from the pLEW90 vector with XhoI and StuI restriction enzymes and used to  
576 replace the neomycin-resistance cassette from the pLEW13\_AAC\_5'/3'UTRs and  
577 pLEW13\_SCS\_5'/3'UTRs construct pre-digested with XhoI and SmaI endonucleases. The  
578 AAC\_ and SCS\_ single knock-out cells were transfected with the NotI-linearized plasmids  
579 followed by selection using hygromycin (5  $\mu$ g/ml). AAC DKO and SCS DKO were grown in the  
580 presence of 2.5  $\mu$ g/ml G418 and 5  $\mu$ g/ml hygromycin.

581 To downregulate expression of SCS, DNA fragment corresponding to 591 bp target sequence  
582 was amplified by PCR from BSF 427 gDNA using gene forward and reverse primers (S5 Table)  
583 extended with BamHI and HindIII restriction sites. The resulting PCR product was digested with  
584 the corresponding enzymes and inserted into digested p2T7-177 plasmid [60]. The single marker  
585 BSF 427 cell line, which bears cassettes for T7 RNAP and tetracycline repressor under  
586 neomycin-resistance marker allowing for inducible expression of dsRNA using tetracycline, was  
587 transfected with the NotI-linearized plasmid. SCS RNAi were kept in G418 and phleomycin  
588 again with induction of RNAi by tetracycline.

589 To generate constructs for the constitutive expression of luciferase targeted to either cytosol or  
590 mitochondrial matrix, the luciferase gene was amplified by PCR using gene specific forward and  
591 reverse primers. To ensure mitochondrial localization of the luciferase, the mtLuc\_FW primer  
592 was extended on its 5' termini with TbIscU mitochondrial targeting sequence [46]. The amplified  
593 *luc\_mito* and *luc\_cyto* genes were digested with BamHI and HindIII restriction enzymes and

594 cloned into the modified pHD1344-tub-B5-3v5 vector (provided by J. Carnes and K. Stuart) that  
595 was pre-digested with the same enzymes to remove the original gene for TbKREPB5. BSF 427,  
596 AAC DKO and SCS DKO cells were transfected with the final NotI-linearized plasmids  
597 pHD1344-tub-mtLUC-3v5 and pHD1344-tub-cytLUC-3v5. The integration into the tubulin  
598 locus ensures constitutive expression of the gene of interest. Luciferase cell line in the BSF 427  
599 background was grown in puromycin and in the background of AAC DKO and SCS DKO cells  
600 were grown in G418, hygromycin, and puromycin.

601 The AAC DKO/ASCT RNAi cell line was generated by transfecting NotI-linearized pLew-  
602 ASCT-SAS construct containing N-terminal fragment of *asct* gene [61] to AAC DKO cell line.  
603 AAC DKO/ASCT RNAi were grown in G418, hygromycin, and phleomycin with the induction  
604 of RNAi by tetracycline.

605 AAC DKO and SCS DKO addback cell lines were generated in the background of the respective  
606 DKO cells. The coding sequences of AAC and SCS were amplified from BSF 427 gDNA using  
607 specific forward and reverse primers that were extended with HindIII and BamHI restrictions  
608 sites. The amplified PCR products were digested and cloned to pT7\_3v5 plasmid containing a  
609 gene for puromycin selection. The AAC or SCS DKO cells were transfected with the NotI-  
610 linearized plasmid. Addback cell lines were grown in the presence of G418, hygromycin, and  
611 puromycin, and the expression of the ectopic alleles was initiated by the addition of 1 $\mu$ g/ml  
612 tetracycline.

613 SCS conditional DKO (cDKO) cell line was generated using SCS single KO cell line which was  
614 transfected with pT7\_3v5\_SCS linearized plasmid. After successful selection with puromycin,  
615 the second allele was replaced using the pLEW90\_SCS\_5'/3'UTRs construct. The transfection  
616 and selection were done in the presence of tetracycline ensuring expression of regulatable SCS.  
617 SCS cDKO was grown in the presence of tetracycline, G418, hygromycin, and phleomycin.  
618 Suppression of the ectopic allele expression was done by washing the cells twice in tetracycline-  
619 free media.

## 620 **Measurement of $\Delta\Psi_m$ using flow cytometry**

621 The  $\Delta\Psi_m$  was determined utilizing the red-fluorescent dye tetramethylrhodamine ethyl ester  
622 (TMRE, Invitrogen). Cells were grown in log-phase for a few days prior the experiment. In a

623 specific case, the cells were pre-treated with oligomycin at the sublethal concentration of 250  
624  $\mu\text{g/ml}$  for 24 hours before the experiment. Then, in total,  $5 \times 10^6$  of oligomycin treated or  
625 untreated cells were pelleted (1,300 g, 10 min, room temperature), resuspended in 1 ml of the  
626 appropriate medium, incubated with 60 nM TMRE for 30 min at 37°C, washed in PBS,  
627 resuspended in PBS-G (PBS, 6 mM glucose) and immediately analyzed by flow cytometry (BD  
628 FACS Canto II Instrument). In the case of oligomycin-treated cells, the 250  $\mu\text{g/ml}$  of oligomycin  
629 was maintained in all buffers and washes. For each sample, 10,000 fluorescent events were  
630 collected. Treatment with the protonophore FCCP (20  $\mu\text{M}$ ) for 10 min was used as a control for  
631 mitochondrial membrane depolarization. Data were evaluated using BD FACSDiva (BD  
632 Company) software.

### 633 **SDS PAGE, Western blots, antibody production**

634 Cell cultures were harvested at 1,300 g at 4°C for 10 minutes, washed with 1x PBS and the  
635 lysates were prepared at concentration  $1 \times 10^7$  cells/30  $\mu\text{l}$  using 1x PBS, 6% sodium dodecyl  
636 sulfate, 300 mM DTT, 150 mM Tris HCl, 30% glycerol, and 0.02% Bromophenol Blue. Samples  
637 were boiled for 7 minutes at 97°C and stored at -20°C. Proteins were resolved on SDS-PAGE  
638 gels (BioRad 4568093, Invitrogen XP04202BOX) using  $10^7$  cells/sample. Proteins were blotted  
639 onto PVDF membrane (Thermo Scientific) and probed with corresponding monoclonal (mAb) or  
640 polyclonal (pAb) antibodies. This was followed by probing with secondary HRP conjugated anti-  
641 mouse or anti-rabbit antibody (1:2,000 dilution, SIGMA). Proteins were visualized using the  
642 Clarity Western ECL substrate (Bio-Rad 1705060EM) on a ChemiDoc instrument (Bio-Rad).  
643 The PageRuler pre-stained protein standard (Fermentas) was used to determine the size of the  
644 detected bands. AAC and SCS pAb were prepared for the purpose of this study. Open reading  
645 frames of AAC and SCS beta subunit were cloned in *E. coli* expression plasmid pSKB3. Proteins  
646 were overexpressed in *E. coli* BL21 cells, solubilized by sarkosyl, and purified by high-  
647 performance liquid chromatography. Antigens were sent to David's Biotechnologie (Germany)  
648 for pAb production. Primary antibodies used in this paper are following: pAb anti-AAC (1:1,000,  
649 34 kDa), pAb anti-SCS (1:1,000, 45 kDa), pAb anti-APRT (1:500, 26 kDa), pAb anti-p18  
650 (1:1,000, 18 kDa) and mAb anti-HSP70 (1:5,000, 72 kDa).

### 651 **Digitonin subcellular fractionation**

652 Whole cell lysates (WCL) were prepared from BSF 427 for SCS localization and cell lines  
653 expressing mitochondrial (mito) or cytosolic (cyto) luciferase. For the digitonin fractionation,  
654  $1 \times 10^8$  cells were harvested and washed with 1x PBS-G. Pellet was resuspended in 500  $\mu$ l of  
655 SoTe (0.6 M Sorbitol, 2 mM EDTA, 20 mM Tris-HCl pH 7.5) and lysed with 500  $\mu$ l of SoTe  
656 with 0.03% digitonin. Samples were incubated on ice for 5 minutes and centrifuged at 7,000 rpm  
657 for 3 minutes at 4°C. The supernatant was harvested as a cytosolic fraction and the pellet was  
658 resuspended in 1x PBS as a mitochondrial fraction. WCL and the fractions were resolved by  
659 SDS-PAGE.

#### 660 **Measurement of $\Delta\Psi_m$ using Safranin O dye**

661 This method was performed as described previously [22]. Briefly, the in situ  $\Delta\Psi_m$  was measured  
662 using Safranin O dye (Sigma, S2255-25G).  $2 \times 10^7$  cells were centrifuged for 10 minutes at room  
663 temperature at 1,300 g and washed with ANT buffer containing 8 mM KCl, 110 mM K-  
664 gluconate, 10 mM Mannitol, 10 mM NaCl, 10 mM free acid HEPES, 10 mM  $K_2HPO_4$ , 0.015  
665 mM EGTA potassium salt, 0.5 mg/ml fatty acid free bovine serum albumin, and 1.5 mM  $MgCl_2$   
666 at pH 7.25. The cell pellet was resuspended with ANT buffer with 4  $\mu$ M digitonin and 5  $\mu$ M  
667 Safranin O. Fluorescence was recorded in a Hitachi F-7100 spectrofluorometer (Hitachi High  
668 Technologies) at a 5-Hz acquisition rate, using 495 nm excitation and 585 nm emission  
669 wavelengths. Samples were measured at room temperature and stirred during the experiment.  
670 Where indicated, 1 mM ATP as a substrate and inhibitors (1  $\mu$ M CATR or 10  $\mu$ M oligomycin)  
671 were added. Finally, the SF6847 uncoupler was used as a control of the maximal depolarization.

#### 672 **SCS activity assay**

673 The organellar pellet from  $5 \times 10^8$  digitonin-fractionated cells was resuspended in ANT buffer,  
674 sonicated 3 times for 10 seconds at 20% power. The sample was spun down at 16,000 g for 5  
675 min and supernatant containing mitochondrial matrix was subjected to SCS activity assay. The  
676 activity was assayed in ANT buffer in the presence of succinyl-CoA (0.2 mM), ADP (2 mM),  
677 Ellman's reagent (5,5'-dithio-bis-[2-nitrobenzoic acid], DNTB (0.2 mM)) at 30°C. The released  
678 CoA-SH reacted with DNTB forming thio-nitrobenzoate anion (TNB) which production in time  
679 was monitored spectrophotometrically at 412 nM using a Tecan Infinite M200 plate reader. One

680 unit is defined as an enzyme activity that converts one nanomole of succinyl CoA to CoA-SH in  
681 1 minute per 1 mg of total protein.

#### 682 **Alamar blue-based cell viability assay**

683 Corresponding *T. brucei* cell lines were plated in transparent 96-well plates in a concentration of  
684  $5 \times 10^3$  cells/ml in 200  $\mu$ l per well. Cells were grown in the presence of different CATR  
685 concentrations between 1  $\mu$ M to 500  $\mu$ M or in the presence of TPMP between 0.3 nM to 500  $\mu$ M  
686 for 72 hours in standard cultivation conditions. After 72 hours 20  $\mu$ l of 125  $\mu$ g/ml of resazurin  
687 (Sigma, R7017-1G) was added to each well. After 24 hours the fluorescence was measured using  
688 Tecan Spark set up for 544 nm wavelength for excitation and 590 nm for emission. Data were  
689 analyzed using GraphPad Prism 9 to establish the EC<sub>50</sub> values.

#### 690 **In vivo ATP measurements**

691  $5 \times 10^6$  cells with constitutively expressed luciferase in cytosol or mitochondrion were  
692 centrifuged at 1,300 g for 7 minutes at room temperature. Cells were washed with 1x PBS and  
693 resuspended in 160  $\mu$ l of HEPES-LUC buffer containing 20 mM HEPES, 116 mM NaCl, 5.6  
694 mM KCl, 8 mM MgSO<sub>4</sub> and 1.8 mM CaCl<sub>2</sub> at pH 7.4. Cells were immediately placed in white  
695 bioluminescence 96 well plates, the background luminescence was measured by the Tecan Spark  
696 and 40  $\mu$ l of 250  $\mu$ M luciferin was injected in each sample. The luminescence was measured for  
697 20 cycles and where indicated 10 mM glucose was injected and changes of luminescence were  
698 recorded for another 35 cycles.

#### 699 **Animal experiments**

700 Groups of 7 mice were used for each of the cell lines. Mice were infected by  $10^5$  cells via 100  $\mu$ l  
701 intraperitoneal injection of either BSF 427, AAC DKO, AAC DKO addback, SCS DKO, and  
702 SCS DKO addback. Mice injected with tetracycline induced addback cell lines were put on  
703 doxycycline (200  $\mu$ g/ml doxycycline and 5% sucrose) drinking regime 24 hours before injection.  
704 Blood samples from a tail prick were diluted in 1x SSC and 3.7% formaldehyde, and the  
705 parasitemia levels were counted using a hemocytometer (Counting Chamber CE NeubauerIMP  
706 DL). Parasitemia counts were observed for 15 days and mice displaying impaired health or a  
707 parasite load over  $10^8$  cells/ml of blood were euthanized.



## 708 **NMR experiments**

709 BSF 427, AAC DKO and SCS DKO trypanosomes were grown in log-phase in HMI11 media  
710 supplemented with the respective drugs.  $10^7$  cells were collected by centrifugation at 1,400 g for  
711 10 minutes at RT and washed with incubation buffer (PBS buffer supplemented with 5 g/L  
712  $\text{NaHCO}_3$ , pH 7.4) with the addition of 1 mM of the respective carbon source. Next, the cells  
713 were incubated in preheated plates until the cells manage to keep cell integrity (validated by  
714 microscopic observation, appr. 2.5 hours) at  $37^\circ\text{C}$  with incubation buffer containing uniformly  
715 labeled  $[\text{U-}^{13}\text{C}]$ -glucose (4 mM) in the presence or absence of the 4 mM amino acid threonine in  
716 a total volume of 1 ml. The same experiment was carried out with ordinary  $^{12}\text{C}$  glucose as the  
717 only carbon source. Following centrifugation at 8,000 g for 1 minute at RT, the supernatant was  
718 collected and a proton NMR ( $^1\text{H}$ -NMR) spectra analysis was performed as described in [31].

## 719 **LC-MS metabolomics**

720 Samples were prepared as described previously (3).  $5 \times 10^7$  cells for each sample were rapidly  
721 cooled down in an ethanol-dry ice bath, centrifuged at 1,300 g for 10 minutes at  $4^\circ\text{C}$ , and washed  
722 with 1x PBS. Pellet was resuspended in 100  $\mu\text{l}$  of extraction solvent containing chloroform,  
723 methanol, and water (1:3:1 volume ratio). Samples were shaken for 1 hour at  $4^\circ\text{C}$ , pelleted at  
724 13,000 g for 10 minutes at  $4^\circ\text{C}$  and the supernatants were stored at  $-80^\circ\text{C}$  until analysis. The  
725 used metabolomic methods were described in detail elsewhere [62, 63]. Briefly, an Orbitrap Q  
726 Exactive Plus mass spectrometer coupled to an LC Dionex Ultimate 3000 (all Thermo Fisher  
727 Scientific, San Jose, CA, USA) was used for metabolite profiling. LC condition: column  
728 SeQuant ZIC-pHILIC 150 mm x 4.6 mm i.d., 5  $\mu\text{m}$ , (Merck KGaA, Darmstadt, Germany); flow  
729 rate of 450  $\mu\text{l}/\text{min}$ ; injection volume of 5  $\mu\text{l}$ ; column temperature of  $35^\circ\text{C}$ ; mobile phase A =  
730 acetonitrile and B = 20 mmol/l aqueous ammonium carbonate (pH 9.2; adjusted with  $\text{NH}_4\text{OH}$ );  
731 gradient: 0 min, 20% B; 20 min, 80% B; 20.1 min, 95% B; 23.3 min, 95% B; 23.4 min, 20% B;  
732 30.0 min 20% B. The Q-Exactive settings were: mass range 70-1050 Daltons; 70,000 resolution;  
733 electrospray ion source operated in the positive and negative modes. Data were processed using  
734 Xcalibur<sup>TM</sup> software, version 4.0 (Thermo Fisher Scientific, San Jose, CA, USA), and an in-  
735 house developed Metabolite Mapper<sup>®</sup> platform containing more than 1,500 metabolites  
736 manually annotated against authentic standards.

## 737 **Mass spectrometry sample preparation, MS measurement, and proteomics data analysis**

738 *T. brucei* BSF 427, SCS and AAC DKO cells ( $10^8$  cells/replicate) were washed three times in 10  
739 ml of phosphate-buffered saline (PBS) and lysed in 6% sodium dodecyl sulfate (SDS), 300 mM  
740 DTT, and 150 mM Tris-HCl (pH 6.8), 30% glycerol, and 0.02% Bromophenol Blue. Samples  
741 were loaded on a NOVEX NuPage 4%-12% gradient gel (Thermo Fisher Scientific, Waltham,  
742 MA), run for 10 minutes at 180 V, and stained with Coomassie G250 (Roth, Karlsruhe,  
743 Germany). Each lane was cut and the minced gel pieces were transferred to an Eppendorf tube  
744 for destaining with 50% ethanol/50 mM ABC buffer pH 8.0. The gel pieces were dried and  
745 subsequently reduced (10 mM DTT/50 mM ABC buffer pH 8.0), alkylated (55 mM  
746 iodoacetamide/50 mM ABC buffer pH 8.0), and digested with 1  $\mu$ g trypsin overnight at 37°C.  
747 The tryptic peptides were eluted from the gel pieces with pure acetonitrile and a mixture of 30%  
748 acetonitrile in 50 mM ABC pH 8.0. The acetonitrile was evaporated in a concentrator  
749 (Eppendorf, Germany) and the peptides stored on a StageTip [64]. The proteomic measurement  
750 was performed on an Exactive 480 mass spectrometer (Thermo Fisher Scientific, Bremen,  
751 Germany) with an online-mounted C18-packed capillary column (New Objective, Woburn, MA)  
752 by eluting along a 90-minute gradient of 2% to 40% acetonitrile using an EasyLC 1200 uHPLC  
753 system (Thermo Fisher Scientific, Bremen, Germany). The mass spectrometer was operated with  
754 a top20 data-dependent acquisition (DDA) mode. Data analysis was performed in MaxQuant  
755 version 1.5.2.8 using the tritrypDB-8.1 *Tbrucei*TREU927\_AnnotatedProteins database (11,567  
756 entries) and standard settings, except activating the match between run feature and the label-free  
757 quantification (LFQ) algorithm. Protein groups marked as contaminants, reverse entries, and  
758 only identified by site were removed prior to bioinformatics analysis, as well as protein groups  
759 with less than 2 peptides (minimum 1 unique). Additional information like gene names and  
760 descriptions were extracted from the fasta header and attached to the individual protein groups.

## 761 **Statistical analysis**

762 The number of replicates, controls, and statistical tests are in accordance with published studies  
763 employing comparable techniques and are generally accepted in the field. Statistical differences  
764 were analyzed with Prism software (version 8.2.1, GraphPad software). Comparisons of two  
765 groups were calculated with two-tailed paired *t* test. A *P* value of less than 0.05 was considered  
766 statistically significant. Quantitative mass spectrometry experiments were performed in four  
767 biological replicates.

## 768 **Supporting information**

### 769 **S1 Fig. Proteomic and metabolomic profiling of AAC DKO cells**

770 (A) Volcano plots showing a comparison of protein expression levels (3654 protein groups)  
771 between BSF 427 and AAC DKO cells. Log<sub>2</sub> fold change values of averaged LFQ intensities  
772 from quadruplicate experiments are plotted against the respective  $-\log_{10}$ -transformed *P* values.  
773 Significantly changed hypothetical proteins are shown in blue, down-regulated cytosolic  
774 ribosomal proteins are shown in dark red. Mitochondrial enzymes involved in amino and keto  
775 acid oxidation including TCA cycle enzymes are highlighted in orange. ME, malic enzyme; IDH,  
776 isocitrate dehydrogenase; SDH1, succinate dehydrogenase subunit 1; AAT, alanine  
777 aminotransferase; PDH E3, subunit of pyruvate dehydrogenase; KDH E2, subunit of  $\alpha$ -  
778 ketoglutarate dehydrogenase; BCKD E2, subunit of branch chain keto acid dehydrogenase;  
779 MPC2, mitochondrial pyruvate carrier 2; MCP14, mitochondrial carrier protein 14. (B) Volcano  
780 plot showing the detected metabolites (124 metabolites) analyzed in BSF 427 and AAC DKO  
781 cells. Log<sub>2</sub> fold change values of the average of mean peak area from quadruplicate experiments  
782 are plotted against the respective  $-\log_{10}$  transformed *P* values. AAs, amino acids.

### 783 **S2 Fig. Proteomic and metabolomic profiling of SCS DKO cells.**

784 (A) Volcano plots showing a comparison of protein expression levels (3,654 protein groups)  
785 between BSF 427 and SCS DKO cells. Log<sub>2</sub> fold change values of averaged LFQ intensities  
786 from quadruplicate experiments are plotted against the respective  $-\log_{10}$ -transformed *P* values.  
787 Significantly changed hypothetical proteins are shown in blue. SCS sub  $\alpha$ , subunit  $\alpha$  of SCS  $\alpha/\beta$   
788 complex. (B) Volcano plot showing the detected metabolites (125 metabolites) analyzed in BSF  
789 427 and AAC DKO cells. Log<sub>2</sub> fold change values of the average of mean peak area from  
790 quadruplicate experiments are plotted against the respective  $-\log_{10}$  transformed *P* values.  
791 Metabolites derived from the reaction of TCA cycle, glutamine/glutamate metabolism,  
792 serin/threonine/alanine/aspartate metabolism, pentose phosphate pathway and oxidative stress  
793 are highlighted in red, green, purple, blue and yellow respectively.  $\alpha$ -KG,  $\alpha$ -ketoglutarate.

794

### 795 **S1 Table. Proteomic analysis of AAC DKO and SCS DKO cells.**

796 Sheet 1 contains Tb927 gene IDs and description for 3,654 protein groups identified by a  
797 minimum of 2 peptides (1 unique) and present in at least two out of four replications. Sheet 2

798 contains protein groups identified in BSF 427 cells and compared to AAC DKO. Sheet 3  
799 contains protein groups differentially expressed ( $\log_2$  fold change  $< -0.4$ ,  $\log_2$  fold change  $>$   
800  $0.5$ ) which passed threshold of  $p$ -value of  $0.05$ . Sheet 4 contains protein groups identified in BSF  
801 427 cells and compared to SCS DKO. Sheet 5 contains protein groups differentially expressed  
802 ( $\log_2$  fold change  $< -0.4$ ,  $\log_2$  fold change  $> 0.5$ ) which passed threshold of  $p$ -value of  $0.05$ .

803 **S2 Table. Metabolomic analysis of AAC DKO cells.** LC-MS metabolomic data.

804 **S2 Table. Metabolomic analysis of SCS DKO cells.** LC-MS metabolomic data.

805 **S4 Table. Excreted end-products from metabolism of glucose and threonine in BSF**  
806 **trypanosomes.** Parasites were incubated with  $4$  mM glucose or with  $[U-^{13}C]$ -glucose with or  
807 without  $4$  mM threonine. ICS (internal carbon source): intracellular carbon source of unknown  
808 origin metabolized by the BSF trypanosomes. Amounts of end-products excreted (here malate)  
809 from the carbon source indicated in brackets, expressed as nmoles excreted per h and per  $10^8$   
810 cells. *nd*: not detectable.

811 **S5 Table. List of oligonucleotides used in the study.**

812

## 813 **Figure legends**

814 **Fig 1. Schematic and simplified representation of possible metabolic pathways related to**  
815 **cytosolic and mitochondrial ATP production.** Enzymes are: ACH, acetyl-CoA thioesterase;  
816 AOX, alternative oxidase; ASCT, acetate:succinate CoA-transferase, Gly-3-P DH, glycerol-3-  
817 phosphate dehydrogenase; KDH,  $\alpha$ -ketoglutarate dehydrogenase; PK, pyruvate kinase; PDH,  
818 pyruvate dehydrogenase complex; SCS, succinyl-CoA synthetase; TDH, threonine  
819 dehydrogenase. Abbreviations:  $\alpha$ -KG,  $\alpha$ -ketoglutarate;  $\Delta\Psi_m$ , mitochondrial membrane potential;  
820 AAC, ATP/ADP carrier; CATR, carboxyatractyloside; OLM, oligomycin; TPMP,  
821 methyltriphenylphosphonium.

822 **Fig 2. The ATP/ADP carrier is dispensable for BSF *T. brucei* viability and for maintaining**  
823 **the  $\Delta\Psi_m$ .**

824 (A) The strategy to generate AAC DKO involved replacement of both alleles with T7 RNA  
825 polymerase and tetracycline repressor linked to genes conferring neomycin and hygromycin

826 resistance, respectively. (B) PCR verification for the elimination of all AAC alleles in AAC  
827 DKO cell line. The primers used are color-coded in (A). (C) Immunoblot analysis of AAC DKO  
828 cells using specific anti-AAC antibody. Immunodetection of mitochondrial hsp 70 served as a  
829 loading control. (D) Growth of AAC DKO cells compared to wild-type BSF 427 in HMI-11  
830 measured for 8 days. (E) Growth of AAC DKO cells compared to wild-type BSF 427 in CMM  
831 medium measured for 7 days. (F) The survival rate of 5 female BALB/c mice which were  
832 intraperitoneally infected with AAC DKO and wild-type BSF 427 parasites. The infected mice  
833 were monitored for 6 days. (G) Flow cytometry analysis of TMRE-stained AAC DKO and BSF  
834 427 cells grown in HMI-11 or CMM medium to measure  $\Delta\Psi_m$ . The addition of FCCP served as  
835 a control for  $\Delta\Psi_m$  depolarization (+FCCP). (means  $\pm$  s.d., n= 6). (H) Flow cytometry analysis of  
836 TMRE-stained AAC DKO and BSF 427 cells grown in HMI-11 medium and treated with 250  
837 ng/ml of oligomycin (+OLM) for 24 hours before the analysis. (means  $\pm$  s.d., n= 6)

838 **Fig 3. In the absence of AAC, the cells are unable to import cytosolic ATP to the**  
839 **mitochondrial matrix.**

840 (A) Mitochondrial membrane polarization detected using Safranin O dye in digitonin-  
841 permeabilized BSF 427 cells in the presence of ATP. Carboxyatractyloside (CATR), the AAC  
842 inhibitor was added before the ATP (red line) as a control for no membrane polarization due to  
843 the inability to import ATP into the mitochondrial matrix. Oligomycin (OLM) was added after  
844 the CATR to induce depolarization. SF6847, an uncoupler, was added to test any further  
845 depolarization. ATP, CATR, OLM and SF 6847 were added where indicated. (B) Mitochondrial  
846 membrane polarization detected using Safranin O dye in digitonin-permeabilized AAC DKO  
847 and AAC DKO Addback cells in the presence of ATP. CATR, OLM and SF 6847 were added  
848 where indicated. The inset shows western blot analysis of BSF 427, AAC DKO Addback cells  
849 grown in the presence or absence of tetracycline, probed with anti-v5 monoclonal antibody, that  
850 recognizes the v5 epitope attached to the 3' end of the *AAC* gene, and anti-mt Hsp70 antibody as  
851 a loading control. (C) Subcellular localization of v5-tagged luciferase without (luc\_cyto) or with  
852 mitochondrial localization signal (luc\_mito) endogenously expressed in BSF 427 and AAC DKO  
853 cells was determined in whole cell lysates and in the corresponding cytosolic and organellar  
854 fractions separated by digitonin extraction. Purified fractions were analyzed by Western blotting  
855 with the following antibodies: anti-v5, anti-mt Hsp70 (mitochondrial marker), and anti-adenosine  
856 phosphoribosyltransferase (APRT) (cytosolic marker). The relevant sizes of the protein marker

857 are indicated on the left. (D) Representative data of basal (first peak) and glucose-induced  
858 (second peak) levels of bioluminescence detected by a plate reader in the cytosol of BSF  
859 427\_luc\_cyto (left panel) and AAC DKO\_luc\_cyto (right panel) using 25  $\mu$ M luciferin. (E)  
860 Quantification of changes in ATP levels upon 5 mM glucose addition in BSF 427\_Luc\_cyto and  
861 AAC DKO\_luc\_cyto. Box and whiskers plots, n=7-10, \*\*\*  $P < 0.001$ . (F) Representative data of  
862 basal (first peak) and glucose-induced (second peak) bioluminescence levels detected by a plate  
863 reader in the mitochondrial matrix of BSF 427\_luc\_mito (left pane) and AAC DKO\_luc\_mito  
864 (right panel) using 25  $\mu$ M luciferin. (G) Quantification of changes in ATP levels upon 5 mM  
865 glucose addition in BSF 427\_Luc\_mito and AAC DKO\_luc\_mito. Box and whiskers plots, n=8-  
866 11, \*\*\*  $P < 0.001$ .

867 **Fig 4. AAC DKO cells are more sensitive to the treatment by TPMP, an inhibitor of  $\alpha$ -**  
868 **ketoglutarate dehydrogenase.**

869 (A) Sensitivity of BSF 427, AAC DKO, AAC DKO\_addback to TPMP estimated by Alamar  
870 blue cell viability assay. (B) AAC DKO/ASCT RNAi noninduced (NON) and cells induced for 4  
871 days (D4) to TPMP estimated by resazurine cell-viability assay. The dose-response curves were  
872 calculated using GraphPad Prism 8.0 software. The calculated  $EC_{50}$  values are shown in graphs  
873 and are expressed in  $\mu$ M. (C) Western blot analysis of BSF 427, AAC DKO and  
874 AACDKO/ASCT RNAi cells uninduced and induced for 2 and 4 days using anti-ASCT  
875 antibody. \*-non-specific band serving as a loading control.

876 **Fig 5. SCS DKO cells are viable in vitro but exert lower virulence in animal model.**

877 (A) The strategy to generate SCS DKO involved replacement of both alleles with resistance  
878 genes conferring neomycin and hygromycin resistance. (B) PCR verification for the elimination  
879 of both SCS alleles in SCS DKO cell line. (C) Immunoblot analysis of SCS DKO cells using  
880 specific anti-SCS antibody. Immunodetection of cytosolic APRT served as a loading control. (D)  
881 Subcellular localization of SCS using BSF 427 cells. WCL, whole cell lysate; Cyt, cytosol; Mito,  
882 mitochondrial; insol, insoluble; sol, soluble. (E) Enzymatic activity of SCS measured in  
883 mitochondrial lysates extracted from BSF 427, AAC DKO and SCS DKO cells. (F) Growth of  
884 AAC DKO cells compared to wild-type BSF 427 in HMI-11 and CMM medium measured for at  
885 least 7 days. (G) The survival rate of 7 female BALB/c mice which were intraperitoneally  
886 infected with SCS DKO and wild-type BSF 427 parasites. The infected mice were monitored for  
887 14 days. (H) The survival rate of 7 female BALB/c mice which were intraperitoneally infected

888 with SCS DKO Addback and wild-type BSF 427 parasites. The SCS DKO Addback infected  
889 mice were supplied with water containing doxycycline to induced expression of the addback  
890 SCS copy. The mice were monitored for 6 days. (I) Immunoblot analysis of BSF 427 and SCS  
891 cDKO cell line inducibly expressing v5-tagged SCS using specific anti-SCS antibody.  
892 Immunodetection of mitochondrial hsp70 served as a loading control. (J) The survival rate of 7  
893 female BALB/c mice which were intraperitoneally infected with BSF 427 and SCS  
894 DKO\_addback parasites.

895

896 **Fig 6. SCS DKO parasites do not excreted acetate**

897 Proton ( $^1\text{H}$ ) NMR analyses of end-products excreted from the metabolism of  $^{13}\text{C}$ -enriched  
898 glucose. BSF 427 (A), SCS DKO (B) and AAC DKO (C) trypanosomes were incubated for 2.5  
899 hours in PBS containing 4 mM  $[\text{U}-^{13}\text{C}]$ -glucose in combination with threonine (+Thr) or  $\alpha$ -  
900 ketoglutarate (+ $\alpha$ -KG) before analysis of the spent medium by  $^1\text{H}$ -NMR spectrometry. The  
901 amounts of each end-product excreted are documented in Table S3. Abbreviations: Ac, acetate;  
902 Al, alanine; L, lactate; Py, pyruvate; S, succinate.

903 **Fig 7. SCS DKO parasites have decreased mitochondrial ATP content, but are capable of**  
904 **ATP import and ATP hydrolysis.**

905 (A) Subcellular localization of V5-tagged luciferase without (luc\_cyto) or with mitochondrial  
906 localization signal (luc\_mito) endogenously expressed in SCS DKO cells was determined in  
907 whole cell lysates and in the corresponding cytosolic and organellar fractions separated by  
908 digitonin extraction. Purified fractions were analyzed by Western blotting with the following  
909 antibodies: anti-v5, anti-mt Hsp70 (mitochondrial marker), and anti-adenosine  
910 phosphoribosyltransferase (APRT) (cytosolic marker). The relevant sizes of the protein marker  
911 are indicated on the left. (B) Immunoblot of V5-tagged luciferase expressed in BSF  
912 427\_luc\_cyto, BSF 427\_luc\_mito, AAC DKO\_luc\_cyto, AAC DKO\_luc\_mito, SCS  
913 DKO\_luc\_cyto, SCS DKO\_luc\_mito cells using antibodies against V5 tag. Antibody against  
914 subunit p18 of FoF1 ATP synthase was used as a loading control. (C) The quantification  
915 analyses of luciferase expression in all cell lines by densitometry. The bars represent relative  
916 protein amounts of luciferase expression in AAC DKO and SCS DKO cells compared to  
917 luciferase expression in BSF 427. (means  $\pm$  s.d., n= 6-7). (D) Representative data of ATP

918 measurements performed in living BSF 427\_luc\_cyto, BSF 427\_luc\_mito, AAC DKO\_luc\_cyto,  
919 AAC DKO\_luc\_mito, SCS DKO\_luc\_cyto, SCS DKO\_luc\_mito cells using 25  $\mu$ M luciferin. (E)  
920 Quantification of the luminescence measurement detected in BSF 427\_luc\_cyto, BSF  
921 427\_luc\_mito, AAC DKO\_luc\_cyto, AAC DKO\_luc\_mito, SCS DKO\_luc\_cyto, SCS  
922 DKO\_luc\_mito. Data shown in the bars are derived from experiments of which representative  
923 graphs are shown in panel D (means  $\pm$  s.d., n= 4-5, Student's unpaired *t*-test, \**P* < 0.05, \*\* *P* <  
924 0.005). (F) Flow cytometry analysis of TMRE-stained SCS DKO and BSF 427 cells grown in  
925 HMI-11 or CMM medium to measure  $\Delta\Psi_m$ . The addition of FCCP served as a control for  $\Delta\Psi_m$   
926 depolarization (+FCCP). (means  $\pm$  s.d., n= 6). (G) Mitochondrial membrane polarization  
927 detected using Safranin O dye in digitonin-permeabilized BSF 427 cells (black/grey lines) and  
928 SCS DKO (light and dark red) in the presence of ATP. ATP, CATR, OLM and SF 6847 were  
929 added where indicated.

930 **Fig 8. SCS DKO cells are more sensitive to CATR, an inhibitor of AAC.**

931 (A) Sensitivity of BSF 427, SCS DKO, ASCT DKO to carboxyatractyloside (CATR) estimated  
932 by Alamar Blue cell-viability assay. The dose-response curves were calculated using GraphPad  
933 Prism 8.0 software. The calculated EC<sub>50</sub> values are shown in graphs and are expressed in mM.  
934 (B) Sensitivity of BSF 427 and SCS DKO, ASCT DKO to bongkreikic acid estimated as in (A).  
935 (C) Sensitivity of BSF 427, SCS cDKO noninduced (-tet) and 4-days induced (+tet) cells to  
936 carboxyatractyloside (CATR) estimated as in (A). (D) Immunoblot of SCS cDKO noninduced (-  
937 tet) and 2-days induced (+tet) cells using SCS antibody. Immunodetection of mitochondrial  
938 hsp70 served as a loading control.

939 **Fig 9. SCS RNAi silencing results in growth phenotype and decreased  $\Delta\Psi_m$  in CMM\_glc  
940 and CMM\_gly medium.**

941 (A) Growth of BSF 427 and SCS DKO cells in HMI-11, CMM\_glc and CMM\_gly medium. (B)  
942 Western blot analysis of whole cell lysates of SCS RNAi non induced and induced (+tet) cells  
943 grown in HMI-11, CMM\_glc and CMM\_gly using antibodies against the SCS protein. The  
944 immunoblot probed with anti-mitochondrial hsp70 antibody served as loading controls. Glc,  
945 glucose; gly, glycerol. (C) Growth of SCS RNAi non induced (non) and tetracycline induced  
946 (IND) cells measured for 8 days in HMI- 11 (left), CMM\_glc (middle) and CMM\_gly (right).  
947 Glc, glucose; gly, glycerol. (D) Flow cytometry analysis of TMRE-stained SCS RNAi



948 noninduced and induced cells grown in HMI- 11 (right), CMM\_glc (middle) and CMM\_gly  
949 (left). (means  $\pm$  s.d., n= 3-9)

950

951 **Fig 10. Schematic visualization of AAC and SCS activities interplay in BSF 427 (A), AAC**  
952 **DKO (B) and SCS DKO (C) grown in HMI-11 and BSF 427 cultured in CMM\_gly medium**  
953 **(D).**

954 AAC, ATP/ADP carrier; SCS, succinyl-CoA synthetase.

955

## 956 **Funding**

957 This work was supported by Czech Science Foundation grant 20-14409S, by European Regional  
958 Development Fund (ERDF) and Ministry of Education, Youth and Sport (MEYS) project  
959 CZ.02.1.01/0.0/0.0/16\_019/0000759 and by the European Research Council (ERC) (MitoSignal,  
960 grant agreement no. 101044951) to AZ. FB and EP were supported by the Centre National de la  
961 Recherche Scientifique (CNRS), the Université de Bordeaux, the Agence Nationale de la  
962 Recherche (ANR) through grants ADIPOTRYP (ANR19-CE15-0004-01) of the ANR  
963 "Générique" call, the Laboratoire d'Excellence (LabEx) ParaFrap ANR-11-LABX-0024 and the  
964 "Fondation pour le Recherche Médicale" (FRM) ("Equipe FRM", grant n°EQU201903007845).

## 965 **References**

- 966 1. Zikova A. Mitochondrial adaptations throughout the Trypanosoma brucei life cycle. J Eukaryot  
967 Microbiol. 2022:e12911. Epub 2022/03/25. doi: 10.1111/jeu.12911. PubMed PMID: 35325490.
- 968 2. Silva Pereira S, Trindade S, De Niz M, Figueiredo LM. Correction to 'Tissue tropism in parasitic  
969 diseases'. Open biology. 2019;9(6):190124. Epub 2019/06/27. doi: 10.1098/rsob.190124. PubMed PMID:  
970 31238821; PubMed Central PMCID: PMC6597756.
- 971 3. Mantilla BS, Marchese L, Casas-Sanchez A, Dyer NA, Egeh N, Biran M, et al. Proline Metabolism is  
972 Essential for Trypanosoma brucei Survival in the Tsetse Vector. PLoS Pathog.  
973 2017;13(1):e1006158. Epub 2017/01/24. doi: 10.1371/journal.ppat.1006158. PubMed PMID: 28114403;  
974 PubMed Central PMCID: PMC5289646.
- 975 4. Millerioux Y, Ebikeme C, Biran M, Morand P, Bouyssou G, Vincent IM, et al. The threonine  
976 degradation pathway of the Trypanosoma brucei procyclic form: the main carbon source for lipid  
977 biosynthesis is under metabolic control. Mol Microbiol. 2013;90(1):114-29. Epub 2013/08/01. doi:  
978 10.1111/mmi.12351. PubMed PMID: 23899193.

- 979 5. Villafranz O, Biran M, Pineda E, Plazolles N, Cahoreau E, Souza ROO, et al. Procyclic trypanosomes  
980 recycle glucose catabolites and TCA cycle intermediates to stimulate growth in the presence of  
981 physiological amounts of proline. *Plos Pathogens*. 2021;17(3). doi: ARTN e1009204  
982 10.1371/journal.ppat.1009204. PubMed PMID: WOS:000625321100005.
- 983 6. Bochud-Allemann N, Schneider A. Mitochondrial substrate level phosphorylation is essential for  
984 growth of procyclic *Trypanosoma brucei*. *J Biol Chem*. 2002;277(36):32849-54. Epub 2002/07/04. doi:  
985 10.1074/jbc.M205776200  
986 M205776200 [pii]. PubMed PMID: 12095995.
- 987 7. Millerioux Y, Morand P, Biran M, Mazet M, Moreau P, Wargnies M, et al. ATP synthesis-coupled  
988 and -uncoupled acetate production from acetyl-CoA by mitochondrial acetate:succinate CoA-transferase  
989 and acetyl-CoA thioesterase in *Trypanosoma*. *J Biol Chem*. 2012;287(21):17186-97. Epub 2012/04/05.  
990 doi: 10.1074/jbc.M112.355404. PubMed PMID: 22474284; PubMed Central PMCID: PMC3366814.
- 991 8. Zikova A, Schnauffer A, Dalley RA, Panigrahi AK, Stuart KD. The F(0)F(1)-ATP synthase complex  
992 contains novel subunits and is essential for procyclic *Trypanosoma brucei*. *PLoS Pathog*.  
993 2009;5(5):e1000436. Epub 2009/05/14. doi: 10.1371/journal.ppat.1000436. PubMed PMID: 19436713;  
994 PubMed Central PMCID: PMC2674945.
- 995 9. Dewar CE, Casas-Sanchez A, Dieme C, Crouzols A, Haines LR, Acosta-Serrano A, et al. Oxidative  
996 Phosphorylation Is Required for Powering Motility and Development of the Sleeping Sickness Parasite  
997 *Trypanosoma brucei* in the Tsetse Fly Vector. *mBio*. 2022:e0235721. Epub 2022/01/12. doi:  
998 10.1128/mbio.02357-21. PubMed PMID: 35012336; PubMed Central PMCID: PMC8749461.
- 999 10. Michels PAM, Villafranz O, Pineda E, Alencar MB, Caceres AJ, Silber AM, et al. Carbohydrate  
1000 metabolism in trypanosomatids: New insights revealing novel complexity, diversity and species-unique  
1001 features. *Exp Parasitol*. 2021;224:108102. Epub 2021/03/30. doi: 10.1016/j.exppara.2021.108102.  
1002 PubMed PMID: 33775649.
- 1003 11. Zikova A, Verner Z, Nenarokova A, Michels PAM, Lukes J. A paradigm shift: The mitoproteomes  
1004 of procyclic and bloodstream *Trypanosoma brucei* are comparably complex. *PLoS Pathog*.  
1005 2017;13(12):e1006679. Epub 2017/12/22. doi: 10.1371/journal.ppat.1006679. PubMed PMID:  
1006 29267392; PubMed Central PMCID: PMC5739487.
- 1007 12. Surve S, Heestand M, Panicucci B, Schnauffer A, Parsons M. Enigmatic presence of mitochondrial  
1008 complex I in *Trypanosoma brucei* bloodstream forms. *Eukaryot Cell*. 2012;11(2):183-93. Epub  
1009 2011/12/14. doi: 10.1128/EC.05282-11. PubMed PMID: 22158713; PubMed Central PMCID:  
1010 PMC3272898.
- 1011 13. Chaudhuri M, Ott RD, Hill GC. Trypanosome alternative oxidase: from molecule to function.  
1012 *Trends Parasitol*. 2006;22(10):484-91. Epub 2006/08/22. doi: S1471-4922(06)00212-1 [pii]  
1013 10.1016/j.pt.2006.08.007. PubMed PMID: 16920028.
- 1014 14. Gualdrón-López M, Brennand A, Hannaert V, Quinones W, Caceres AJ, Bringaud F, et al. When,  
1015 how and why glycolysis became compartmentalised in the Kinetoplastea. A new look at an ancient  
1016 organelle. *Int J Parasitol*. 2012;42(1):1-20. Epub 2011/12/07. doi: 10.1016/j.ijpara.2011.10.007. PubMed  
1017 PMID: 22142562.
- 1018 15. Nolan DP, Voorheis HP. The mitochondrion in bloodstream forms of *Trypanosoma brucei* is  
1019 energized by the electrogenic pumping of protons catalysed by the F1F0-ATPase. *Eur J Biochem*.  
1020 1992;209(1):207-16. Epub 1992/10/01. PubMed PMID: 1327770.
- 1021 16. Schnauffer A, Clark-Walker GD, Steinberg AG, Stuart K. The F1-ATP synthase complex in  
1022 bloodstream stage trypanosomes has an unusual and essential function. *EMBO J*. 2005;24(23):4029-40.  
1023 Epub 2005/11/05. doi: 7600862 [pii]

- 1024 10.1038/sj.emboj.7600862. PubMed PMID: 16270030; PubMed Central PMCID: PMC1356303.
- 1025 17. Chinopoulos C, Adam-Vizi V. Mitochondria as ATP consumers in cellular pathology. *Biochim*
- 1026 *Biophys Acta*. 2010;1802(1):221-7. Epub 2009/09/01. doi: 10.1016/j.bbadis.2009.08.008. PubMed PMID:
- 1027 19715757.
- 1028 18. Chinopoulos C. Mitochondrial consumption of cytosolic ATP: Not so fast. *Febs Letters*.
- 1029 2011;585(9):1255-9. doi: 10.1016/j.febslet.2011.04.004. PubMed PMID: WOS:000290248300001.
- 1030 19. Chinopoulos C. The "B space" of mitochondrial phosphorylation. *J Neurosci Res*.
- 1031 2011;89(12):1897-904. Epub 2011/05/05. doi: 10.1002/jnr.22659. PubMed PMID: 21541983.
- 1032 20. St-Pierre J, Brand MD, Boutilier RG. Mitochondria as ATP consumers: cellular treason in anoxia.
- 1033 *Proc Natl Acad Sci U S A*. 2000;97(15):8670-4. Epub 2000/07/13. doi: 10.1073/pnas.140093597
- 1034 140093597 [pii]. PubMed PMID: 10890886; PubMed Central PMCID: PMC27006.
- 1035 21. Chen WW, Birsoy K, Mihaylova MM, Snitkin H, Stasinski I, Yucel B, et al. Inhibition of ATP1F1
- 1036 ameliorates severe mitochondrial respiratory chain dysfunction in mammalian cells. *Cell reports*.
- 1037 2014;7(1):27-34. Epub 2014/04/02. doi: 10.1016/j.celrep.2014.02.046. PubMed PMID: 24685140;
- 1038 PubMed Central PMCID: PMC4040975.
- 1039 22. Hierro-Yap C, Subrtova K, Gahura O, Panicucci B, Dewar C, Chinopoulos C, et al. Bioenergetic
- 1040 consequences of FoF1-ATP synthase/ATPase deficiency in two life cycle stages of *Trypanosoma brucei*. *J*
- 1041 *Biol Chem*. 2021;296:100357. Epub 2021/02/05. doi: 10.1016/j.jbc.2021.100357. PubMed PMID:
- 1042 33539923; PubMed Central PMCID: PMCPMC7949148.
- 1043 23. Subrtova K, Panicucci B, Zikova A. ATPaseTb2, a Unique Membrane-bound FoF1-ATPase
- 1044 Component, Is Essential in Bloodstream and Dyskinetoplastic Trypanosomes. *PLoS Pathog*.
- 1045 2015;11(2):e1004660. Epub 2015/02/26. doi: 10.1371/journal.ppat.1004660. PubMed PMID: 25714685.
- 1046 24. Gahura O, Subrtova K, Vachova H, Panicucci B, Fearnley IM, Harbour ME, et al. The F1 -ATPase
- 1047 from *Trypanosoma brucei* is elaborated by three copies of an additional p18-subunit. *FEBS J*.
- 1048 2018;285(3):614-28. Epub 2017/12/17. doi: 10.1111/febs.14364. PubMed PMID: 29247468.
- 1049 25. Panicucci B, Gahura O, Zikova A. *Trypanosoma brucei* TbIF1 inhibits the essential F1-ATPase in
- 1050 the infectious form of the parasite. *PLoS Negl Trop Dis*. 2017;11(4):e0005552. Epub 2017/04/18. doi:
- 1051 10.1371/journal.pntd.0005552. PubMed PMID: 28414727; PubMed Central PMCID: PMC5407850.
- 1052 26. Pena-Diaz P, Pelosi L, Ebikeme C, Colasante C, Gao F, Bringaud F, et al. Functional
- 1053 characterization of TbMCP5, a conserved and essential ADP/ATP carrier present in the mitochondrion of
- 1054 the human pathogen *Trypanosoma brucei*. *J Biol Chem*. 2012;287(50):41861-74. Epub 2012/10/18. doi:
- 1055 10.1074/jbc.M112.404699. PubMed PMID: 23074217; PubMed Central PMCID: PMC3516734.
- 1056 27. Gnipova A, Subrtova K, Panicucci B, Horvath A, Lukes J, Zikova A. The ADP/ATP carrier and its
- 1057 relationship to OXPHOS in an ancestral protist, *Trypanosoma brucei*. *Eukaryot Cell*. 2015. Epub
- 1058 2015/01/27. doi: 10.1128/EC.00238-14. PubMed PMID: 25616281.
- 1059 28. Vickerman K. Polymorphism and mitochondrial activity in sleeping sickness trypanosomes.
- 1060 *Nature*. 1965;208(5012):762-6. Epub 1965/11/20. PubMed PMID: 5868887.
- 1061 29. Prochazkova M, Panicucci B, Zikova A. Cultured bloodstream *Trypanosoma brucei* adapt to life
- 1062 without mitochondrial translation release factor 1. *Scientific reports*. 2018;8(1):5135. Epub 2018/03/25.
- 1063 doi: 10.1038/s41598-018-23472-6. PubMed PMID: 29572512; PubMed Central PMCID: PMC5865105.
- 1064 30. Dean S, Gould MK, Dewar CE, Schnauffer AC. Single point mutations in ATP synthase compensate
- 1065 for mitochondrial genome loss in trypanosomes. *Proc Natl Acad Sci U S A*. 2013;110(36):14741-6. Epub
- 1066 2013/08/21. doi: 10.1073/pnas.1305404110. PubMed PMID: 23959897; PubMed Central PMCID:
- 1067 PMC3767566.
- 1068 31. Dejung M, Subota I, Bucerius F, Dindar G, Freiwald A, Engstler M, et al. Quantitative Proteomics
- 1069 Uncovers Novel Factors Involved in Developmental Differentiation of *Trypanosoma brucei*. *PLoS Pathog*.

1070 2016;12(2):e1005439. Epub 2016/02/26. doi: 10.1371/journal.ppat.1005439. PubMed PMID: 26910529;  
1071 PubMed Central PMCID: PMC4765897.

1072 32. Johnston K, Kim DH, Kerkhoven EJ, Burchmore R, Barrett MP, Achcar F. Mapping the metabolism  
1073 of five amino acids in bloodstream form *Trypanosoma brucei* using U-C-13-labelled substrates and LC-  
1074 MS. *Bioscience Rep.* 2019;39. doi: Artn Bsr20181601  
1075 10.1042/Bsr20181601. PubMed PMID: WOS:000469168400001.

1076 33. Creek DJ, Mazet M, Achcar F, Anderson J, Kim DH, Kamour R, et al. Probing the metabolic  
1077 network in bloodstream-form *Trypanosoma brucei* using untargeted metabolomics with stable isotope  
1078 labelled glucose. *PLoS Pathog.* 2015;11(3):e1004689. Epub 2015/03/17. doi:  
1079 10.1371/journal.ppat.1004689. PubMed PMID: 25775470; PubMed Central PMCID: PMC4361558.

1080 34. Mazet M, Morand P, Biran M, Bouyssou G, Courtois P, Daulouede S, et al. Revisiting the central  
1081 metabolism of the bloodstream forms of *Trypanosoma brucei*: production of acetate in the  
1082 mitochondrion is essential for parasite viability. *PLoS Negl Trop Dis.* 2013;7(12):e2587. Epub  
1083 2013/12/25. doi: 10.1371/journal.pntd.0002587. PubMed PMID: 24367711; PubMed Central PMCID:  
1084 PMC3868518.

1085 35. Van Hellemond JJ, Opperdoes FR, Tielens AGM. *Trypanosomatidae* produce acetate via a  
1086 mitochondrial acetate : succinate CoA transferase. *P Natl Acad Sci USA.* 1998;95(6):3036-41. doi: DOI  
1087 10.1073/pnas.95.6.3036. PubMed PMID: WOS:000072596200060.

1088 36. Mochizuki K, Inaoka DK, Mazet M, Shiba T, Fukuda K, Kurasawa H, et al. The ASCT/SCS cycle fuels  
1089 mitochondrial ATP and acetate production in *Trypanosoma brucei*. *Bba-Bioenergetics.* 2020;1861(11).  
1090 doi: ARTN 148283  
1091 10.1016/j.bbabbio.2020.148283. PubMed PMID: WOS:000562511300017.

1092 37. Bienen EJ, Maturi RK, Pollakis G, Clarkson AB, Jr. Non-cytochrome mediated mitochondrial ATP  
1093 production in bloodstream form *Trypanosoma brucei*. *Eur J Biochem.* 1993;216(1):75-80. Epub  
1094 1993/08/15. PubMed PMID: 8365419.

1095 38. Franco JR, Cecchi G, Paone M, Diarra A, Grout L, Kadima Ebeja A, et al. The elimination of human  
1096 African trypanosomiasis: Achievements in relation to WHO road map targets for 2020. *PLoS Negl Trop*  
1097 *Dis.* 2022;16(1):e0010047. Epub 2022/01/19. doi: 10.1371/journal.pntd.0010047. PubMed PMID:  
1098 35041668; PubMed Central PMCID: PMCPMC8765662.

1099 39. Alkhalidi AA, Martinek J, Panicucci B, Dardonville C, Zikova A, de Koning HP. Trypanocidal action  
1100 of bisphosphonium salts through a mitochondrial target in bloodstream form *Trypanosoma brucei*.  
1101 *International journal for parasitology Drugs and drug resistance.* 2016;6(1):23-34. Epub 2016/04/08. doi:  
1102 10.1016/j.ijpddr.2015.12.002. PubMed PMID: 27054061; PubMed Central PMCID: PMC4805778.

1103 40. Lanteri CA, Tidwell RR, Meshnick SR. The mitochondrion is a site of trypanocidal action of the  
1104 aromatic diamidine DB75 in bloodstream forms of *Trypanosoma brucei*. *Antimicrob Agents Chemother.*  
1105 2008;52(3):875-82. Epub 2007/12/19. doi: AAC.00642-07 [pii]  
1106 10.1128/AAC.00642-07. PubMed PMID: 18086841; PubMed Central PMCID: PMC2258549.

1107 41. Eze AA, Gould MK, Munday JC, Tagoe DN, Stelmanis V, Schnauffer A, et al. Reduced  
1108 Mitochondrial Membrane Potential Is a Late Adaptation of *Trypanosoma brucei* to  
1109 Isometamidium Preceded by Mutations in the gamma Subunit of the F1Fo-ATPase. *PLoS Negl Trop Dis.*  
1110 2016;10(8):e0004791. Epub 2016/08/16. doi: 10.1371/journal.pntd.0004791. PubMed PMID: 27518185;  
1111 PubMed Central PMCID: PMCPMC4982688.

1112 42. Carruthers LV, Munday JC, Ebiloma GU, Steketee P, Jayaraman S, Campagnaro GD, et al.  
1113 Diminazene resistance in *Trypanosoma congolense* is not caused by reduced transport capacity but  
1114 associated with reduced mitochondrial membrane potential. *Mol Microbiol.* 2021. Epub 2021/05/02.  
1115 doi: 10.1111/mmi.14733. PubMed PMID: 33932053.

- 1116 43. Wilkes JM, Mulugeta W, Wells C, Peregrine AS. Modulation of mitochondrial electrical potential:  
1117 a candidate mechanism for drug resistance in African trypanosomes. *Biochem J.* 1997;326 ( Pt 3)(Pt  
1118 3):755-61. Epub 1997/10/23. doi: 10.1042/bj3260755. PubMed PMID: 9307025; PubMed Central  
1119 PMCID: PMCPMC1218730.
- 1120 44. Creek DJ, Nijagal B, Kim DH, Rojas F, Matthews KR, Barrett MP. Metabolomics guides rational  
1121 development of a simplified cell culture medium for drug screening against *Trypanosoma brucei*.  
1122 *Antimicrob Agents Chemother.* 2013;57(6):2768-79. Epub 2013/04/11. doi: 10.1128/AAC.00044-13.  
1123 PubMed PMID: 23571546; PubMed Central PMCID: PMC3716122.
- 1124 45. Figueira TR, Melo DR, Vercesi AE, Castilho RF. Safranin as a fluorescent probe for the evaluation  
1125 of mitochondrial membrane potential in isolated organelles and permeabilized cells. *Methods Mol Biol.*  
1126 2012;810:103-17. Epub 2011/11/08. doi: 10.1007/978-1-61779-382-0\_7. PubMed PMID: 22057563.
- 1127 46. Mach J, Poliak P, Matuskova A, Zarsky V, Janata J, Lukes J, et al. An Advanced System of the  
1128 Mitochondrial Processing Peptidase and Core Protein Family in *Trypanosoma brucei* and Multiple Origins  
1129 of the Core I Subunit in Eukaryotes. *Genome Biol Evol.* 2013;5(5):860-75. Epub 2013/04/09. doi:  
1130 10.1093/gbe/evt056. PubMed PMID: 23563972; PubMed Central PMCID: PMCPMC3673636.
- 1131 47. Alexander PB, Wang J, McKnight SL. Targeted killing of a mammalian cell based upon its  
1132 specialized metabolic state. *Proc Natl Acad Sci U S A.* 2011;108(38):15828-33. Epub 2011/09/08. doi:  
1133 10.1073/pnas.1111312108. PubMed PMID: 21896756; PubMed Central PMCID: PMCPMC3179072.
- 1134 48. Elkalaf M, Tuma P, Weiszenstein M, Polak J, Trnka J. Mitochondrial Probe  
1135 Methyltriphenylphosphonium (TPMP) Inhibits the Krebs Cycle Enzyme 2-Oxoglutarate Dehydrogenase.  
1136 *PLoS One.* 2016;11(8):e0161413. Epub 2016/08/19. doi: 10.1371/journal.pone.0161413. PubMed PMID:  
1137 27537184; PubMed Central PMCID: PMCPMC4990249.
- 1138 49. Pineda E, Thonnus M, Mazet M, Mourier A, Cahoreau E, Kulyk H, et al. Glycerol supports growth  
1139 of the *Trypanosoma brucei* bloodstream forms in the absence of glucose: Analysis of metabolic  
1140 adaptations on glycerol-rich conditions. *PLoS Pathog.* 2018;14(11):e1007412. Epub 2018/11/02. doi:  
1141 10.1371/journal.ppat.1007412. PubMed PMID: 30383867.
- 1142 50. Kovarova J, Nagar R, Faria J, Ferguson MAJ, Barrett MP, Horn D. Gluconeogenesis using glycerol  
1143 as a substrate in bloodstream-form *Trypanosoma brucei*. *PLoS Pathog.* 2018;14(12):e1007475. Epub  
1144 2018/12/28. doi: 10.1371/journal.ppat.1007475. PubMed PMID: 30589893; PubMed Central PMCID:  
1145 PMC6307712.
- 1146 51. Trindade S, Rijo-Ferreira F, Carvalho T, Pinto-Neves D, Guegan F, Aresta-Branco F, et al.  
1147 *Trypanosoma brucei* Parasites Occupy and Functionally Adapt to the Adipose Tissue in Mice. *Cell Host*  
1148 *Microbe.* 2016;19(6):837-48. Epub 2016/05/31. doi: 10.1016/j.chom.2016.05.002. PubMed PMID:  
1149 27237364; PubMed Central PMCID: PMC4906371.
- 1150 52. Capewell P, Cren-Travaille C, Marchesi F, Johnston P, Clucas C, Benson RA, et al. The skin is a  
1151 significant but overlooked anatomical reservoir for vector-borne African trypanosomes. *eLife.* 2016;5.  
1152 Epub 2016/09/23. doi: 10.7554/eLife.17716. PubMed PMID: 27653219; PubMed Central PMCID:  
1153 PMC5065312.
- 1154 53. Riviere L, Moreau P, Allmann S, Hahn M, Biran M, Plazolles N, et al. Acetate produced in the  
1155 mitochondrion is the essential precursor for lipid biosynthesis in procyclic trypanosomes. *Proc Natl Acad*  
1156 *Sci U S A.* 2009;106(31):12694-9. Epub 2009/07/25. doi: 10.1073/pnas.0903355106. PubMed PMID:  
1157 19625628; PubMed Central PMCID: PMC2722340.
- 1158 54. Millerioux Y, Mazet M, Bouyssou G, Allmann S, Kiema TR, Bertiaux E, et al. De novo biosynthesis  
1159 of sterols and fatty acids in the *Trypanosoma brucei* procyclic form: Carbon source preferences and  
1160 metabolic flux redistributions. *PLoS Pathog.* 2018;14(5):e1007116. Epub 2018/05/31. doi:  
1161 10.1371/journal.ppat.1007116. PubMed PMID: 29813135; PubMed Central PMCID: PMC5993337.
- 1162 55. Sykes SE, Hajduk SL. Dual functions of alpha-ketoglutarate dehydrogenase E2 in the Krebs cycle  
1163 and mitochondrial DNA inheritance in *Trypanosoma brucei*. *Eukaryot Cell.* 2013;12(1):78-90. Epub

- 1164 2012/11/06. doi: 10.1128/EC.00269-12. PubMed PMID: 23125353; PubMed Central PMCID:  
1165 PMC3535839.
- 1166 56. Spitznagel D, Ebikeme C, Biran M, Nic a' Bhaird N, Bringaud F, Henehan GT, et al. Alanine  
1167 aminotransferase of *Trypanosoma brucei*--a key role in proline metabolism in procyclic life forms. *FEBS J.*  
1168 2009;276(23):7187-99. Epub 2009/11/10. doi: 10.1111/j.1742-4658.2009.07432.x. PubMed PMID:  
1169 19895576.
- 1170 57. Steiger RF, Opperdoes FR, Bontemps J. Subcellular fractionation of *Trypanosoma brucei*  
1171 bloodstream forms with special reference to hydrolases. *Eur J Biochem.* 1980;105(1):163-75. Epub  
1172 1980/03/01. doi: 10.1111/j.1432-1033.1980.tb04486.x. PubMed PMID: 6245876.
- 1173 58. Billington K, Halliday C, Madden R, Dyer P, Barker AR, Moreira-Leite FF, et al. Genome-wide  
1174 subcellular protein map for the flagellate parasite *Trypanosoma brucei*. *Nature microbiology.*  
1175 2023;8(3):533-47. Epub 2023/02/23. doi: 10.1038/s41564-022-01295-6. PubMed PMID: 36804636;  
1176 PubMed Central PMCID: PMC9981465.
- 1177 59. Wirtz E, Leal S, Ochatt C, Cross GA. A tightly regulated inducible expression system for  
1178 conditional gene knock-outs and dominant-negative genetics in *Trypanosoma brucei*. *Mol Biochem*  
1179 *Parasitol.* 1999;99(1):89-101. Epub 1999/04/24. doi: S016668519900002X [pii]. PubMed PMID:  
1180 10215027.
- 1181 60. Wickstead B, Ersfeld K, Gull K. Targeting of a tetracycline-inducible expression system to the  
1182 transcriptionally silent minichromosomes of *Trypanosoma brucei*. *Mol Biochem Parasitol.* 2002;125(1-  
1183 2):211-6. Epub 2002/12/07. doi: S0166685102002384 [pii]. PubMed PMID: 12467990.
- 1184 61. Riviere L, van Weelden SW, Glass P, Vegh P, Coustou V, Biran M, et al. Acetyl:succinate CoA-  
1185 transferase in procyclic *Trypanosoma brucei*. Gene identification and role in carbohydrate metabolism. *J*  
1186 *Biol Chem.* 2004;279(44):45337-46. Epub 2004/08/25. doi: 10.1074/jbc.M407513200  
1187 M407513200 [pii]. PubMed PMID: 15326192.
- 1188 62. Skodova-Sverakova I, Zahonova K, Juricova V, Danchenko M, Moos M, Barath P, et al. Highly  
1189 flexible metabolism of the marine euglenozoan protist *Diplonema papillatum*. *BMC biology.*  
1190 2021;19(1):251. Epub 2021/11/26. doi: 10.1186/s12915-021-01186-y. PubMed PMID: 34819072;  
1191 PubMed Central PMCID: PMC9981465.
- 1192 63. Moos M, Korbelova J, Stetina T, Opekar S, Simek P, Grgac R, et al. Cryoprotective Metabolites  
1193 Are Sourced from Both External Diet and Internal Macromolecular Reserves during Metabolic  
1194 Reprogramming for Freeze Tolerance in *Drosophilid* Fly, *Chymomyza costata*. *Metabolites.* 2022;12(2).  
1195 Epub 2022/02/26. doi: 10.3390/metabo12020163. PubMed PMID: 35208237; PubMed Central PMCID:  
1196 PMC9981465.
- 1197 64. Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation  
1198 and storage of peptides for proteomics using StageTips. *Nature protocols.* 2007;2(8):1896-906. Epub  
1199 2007/08/19. doi: 10.1038/nprot.2007.261. PubMed PMID: 17703201.